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CHAPTER 1: INTRODUCTION 
1.1 Introduction  
Vaccination is one of the most important accomplishments of medicine, resulting 
in a cost-effective strategy for controlling infectious diseases [1]. As stated by the 
vaccinologist, Stanley Plotkin, the impact of vaccination has been enormous in terms of 
mortality reduction, even greater than antibiotics [2]. Vaccination has made possible the 
eradication of smallpox, the elimination in certain regions of the world of infectious 
diseases such as measles and poliomyelitis, and the reduction of morbidity and 
mortality caused by diseases as tetanus and diphtheria [1]. However, acute respiratory 
infections, such as pneumonia and influenza, are only partially controlled by vaccines 
[3]. In addition, the threat of bioterrorism attacks using bioweapons or pathogens [4, 5] 
has added a sense of urgency to the effort to improve safety and efficacy of vaccines 
[6]. The emergence of new antigens, including recombinant proteins which are poorly 
immunogenic, is generating the need to design novel and more potent immune 
adjuvants for the development of efficacious vaccine formulations.   
Influenza has recently gained significant attention because of the possibility of 
rapidly emerging strains that might cause a pandemic outbreak. The 1918-19 pandemic, 
also referred to as “Spanish flu”, caused at least 20 million deaths [7]. In addition, recent 
concerns due to the advent of pathogenic H5N1 strains, which have been responsible 
for higher mortality rates than anticipated, have led to the thought that a pandemic strain 
of influenza is likely to emerge in the near future [8]. As a second example, pneumonia 
is the leading cause of death in infants under five years old. This is a disease that is 
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aggravated by poverty, malnutrition, air pollution, and the presence of other infectious 
diseases. It is also a serious problem for adults over 65 years old [3]. Other agents that 
represent a potential problem because of their likelihood to be used as bioterrorism 
agents include anthrax, plague, Q fever, and tularemia [9].  
Advances in pharmaceutical and biotechnological research have resulted in the 
discovery and creation of new biomolecules, including recombinant proteins and 
nucleic-acid-based molecules, as promising therapies and treatments. To keep pace, 
there needs to be a dramatic increase in efforts to develop new delivery technologies. 
The main objective of these efforts is to overcome challenges such as: protein stability 
and preservation of bioactivity, protection against enzymatic degradation and pH 
instabilities, and controlled release of the therapeutic agent at physiological conditions 
[10, 11].  
In the vaccination area, recent efforts have focused on the production of 
recombinant proteins as specific antigens. These technologies have emerged from the 
need to look for alternatives to live or killed whole organism vaccines, which generally 
had safety issues (e.g., local and systemic reactions such as inflammation, granulomas, 
ulcers, necrosis, etc.) [12]. However, this new generation of technologies poses 
challenges not only in the development of these molecules, but also in terms of 
maintaining their immunogenic potency and mechanisms to administer them. The need 
for effective and safe delivery devices with adjuvant properties is clear and it has driven 
the rational design of vaccine formulations utilizing biodegradable materials, including 
polyesters and polyanhydrides, among other technologies, as adjuvants and delivery 
vehicles [13-15].  
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In addition to adjuvanticity, biocompatibility, and controlled release, targeting the 
vaccine to immune cells has emerged as a viable and powerful strategy. In this context, 
potent adjuvants are being developed utilizing two main targeting strategies: targeted 
delivery (i.e., controlling the site and time of release, as well as the fate of the delivery 
system according to physical conditions – such as size and chemistry) and targeting of 
receptors (i.e., controlling immunological stimulation by targeting specific receptors).  
It has been proposed that the components of effective vaccines are: a delivery 
system, an immune potentiator or adjuvant, and an antigen [16]. In this regard, 
polyanhydride particles have emerged as an important platform, capable of performing 
the dual functions of serving as an adjuvant and as a delivery system. Recently, Ulery 
and co-workers reported on a vaccine formulation that included the integration of a 
controlled delivery system that also served as an immune potentiator (an amphiphilic 
polyanhydride chemistry), an immune-inducing agent (soluble antigen), and an antigen 
(encapsulated antigen) [17]. The main goal of this thesis is to confer targeting properties 
to this vaccine formulation that directs the previously mentioned components towards a 
potent and long lasting immune response (Figure 1.1). In other words, the selection of 
targeting agents (depending upon the specific pathogen) would be key to enhance and 
direct the immune response in a specific manner to achieve protection.  
There is a critical need for the development of efficacious vaccines against 
respiratory pathogens capable of inducing robust and protective immune responses at 
mucosal surfaces. Intranasal application of vaccines can trigger an appropriate immune 
response at systemic and mucosal sites. Intranasal vaccination promotes a more 
effective, earlier, and stronger immune response in comparison to other routes of 
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administration [18]. Since this dissertation focuses on intranasal vaccines against 
respiratory pathogens, alveolar macrophages were the main subject of study; these 
cells are the key immune cells in the lung immunity (see Chapter 2, Section 2.3). 
Polyanhydride nanoparticles are promising vaccine platforms that have the 
potential to be used as controlled drug delivery devices as well as potent and effective 
immune adjuvants for the design of single dose vaccines [15, 19, 20]. It has been 
shown that changing the chemistry of these nanoparticles can change their uptake by 
immune cells and the resultant immune response can be tailored [21, 22]. In addition 
their pathogen mimicking properties have been investigated [17]. Based on these 
studies, new strategies can be exploited in the rational design of these adjuvants, 
mimicking in a more direct manner how immune cells recognize pathogens. Targeting 
pattern-recognition receptors (PRRs) (i.e., C-type lectin receptors or CLRs) provides a 
valuable tool to improve internalization, antigen presentation, and depending on the 
target, enhancement of the immune response.  
The overall goal of this project is to design a targeted nanovaccine platform by 
functionalizing the surface of amphiphilic polyanhydride nanoparticles to target specific 
C-type lectin receptors (CLRs). This study focuses on amphiphilic polyanhydrides based 
on 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) (Figure 1.2). The saccharides used to modify the 
surface of CPTEG:CPH nanoparticles are di-mannose and galactose. 
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Figure 1.1 Components of effective vaccines.  (A) represents the components of an effective 
vaccine, including a delivery system, an immune potentiator or adjuvant and antigen (part A of 
the figure was adapted but modified from O’Hagan 2007 [16]). (B) represents the proposed 
platform for the rational design of vaccines that integrates a controlled delivery system and an 
immune potentiator, an immune-inducing agent, an antigen and a targeting agent to enhance 
the efficacy of vaccines. 
 
 
 
Figure 1.2 Polyanhydride chemical structures. Chemical structures of (A) 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and (B) 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). 
 
 
6 
 
1.2 Dissertation Organization  
Chapter 2 presents a literature review in the areas of on hydrolytically 
degradable polymers used as vaccine adjuvants and delivery systems, immunological 
aspects of vaccine design, and current targeting strategies. Chapter 3 presents the 
overall research goals of this project. The development of high throughput methods to 
fabricate novel polyanhydride nanoparticles with a targeting ligand (i.e., carbohydrates 
to target C-type lectin receptors) is presented in Chapter 4. The interaction between 
nanoparticles and alveolar macrophages (AM) and the role of surface functionalization 
on the internalization of nanoparticles and further activation of AM is presented in 
Chapter 5. Chapter 6 concludes the thesis with some directions for future research. 
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
2.1 Introduction 
This dissertation focuses on the design of nanoparticles modified with 
carbohydrates, which can potentially be used as targeted adjuvants for intranasal 
vaccines. This chapter is organized into the following sections: biodegradable polymers 
used as vaccine adjuvants and delivery systems (Section 2.2), immunological aspects 
of vaccine design (Section 2.3), and targeted vaccine design (Section 2.4).  
Polymeric particles have been used as delivery devices for drugs and bioactive 
molecules. The efficacy of these devices depends on the interaction of the polymer with 
the payload as well with the biological environment. Investigations have focused on the 
effect of chemistry, size, surface charge, and erosion mechanism on the delivery of 
many agents. In particular, for the design of intranasal vaccines, only a few 
biodegradable polymers have been investigated. The rational design of vaccines 
requires an in-depth understanding of the immune system, including the connection 
between innate and adaptive immunities.  
Pathogen mimicking strategies for vaccine design include the rational design of 
the vaccine formulation so it can elicit a similar immune response to the one generated 
by the pathogen but without the non-desirable effects of the infection. Selecting the 
route of immunization is fundamental, so that the immune response can be generated at 
the site of infection, or in other words, where the pathogen is more likely to be 
encountered. For respiratory pathogens, intranasal vaccines are promising for the 
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generation of local and systemic immunity. Engineering intranasal vaccines requires a 
comprehension of the lung immunity including its regulatory mechanisms. 
2.2 Biodegradable polymers as delivery systems 
2.2.1 Introduction  
Biodegradable polymer-based microparticles (diameter > 1µm) and nanoparticles 
(diameter < 1µm) have been used as delivery devices in order to improve the 
therapeutic value of various drugs and bioactive molecules [1, 2]. Biodegradable 
polymers include hydrolytically degradable polymers as well as enzymatic degradable 
polymers, which may be synthetic or natural [3]. The goal is to overcome several 
challenges including preservation of stability, improved bioavailability, preservation of 
bioactivity and biocompatibility, protection against enzymatic degradation and pH 
instabilities, targeted delivery to specific cells and or tissues enabling transport across 
biological barriers, and enhancement of the retention time and controlled release [1, 4-
13]. The performance of particulate devices as drug delivery carriers depends on 
particle size, surface and matrix chemistry, and their interactions with the payload and 
biological systems [1, 2, 14]. 
A successful delivery vehicle has a high loading capacity to reduce the amount of 
the carrier required for administration [1, 15]. In addition, controlled release of a drug or 
bioactive molecule is desirable to reduce frequency of doses and maintain appropriate 
concentrations at local and systemic levels [16]. Controlled release may be pulsatile or 
continuous and Figure 2.1 shows these release profiles in comparison with 
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conventional administration. The use of biodegradable polymers is more efficient for the 
continuous release of a drug/bioactive molecule over time.  
 
 
 
Figure 2.1 Release profile schemes. Conventional release (─) of a drug or bioactive molecule 
requires multiple doses in order to maintain the drug concentration in the therapeutic range (). 
In this case, the drug concentration rapidly falls into the non-therapeutic range (). If the initial 
serum concentration of the drug is too high, initial concentration of the drug is avoided in order 
to prevent the systemic concentration may become toxic (). Controlled release devices are 
designed so that the release can be continuous (─) or pulsatile (─), in order to maintain the drug 
concentration within the therapeutic range. Modified and adapted from Brannon-Peppas [16]. 
 
There are three mechanisms of incorporating a drug/bioactive molecule into 
polymeric particles: loading at the time of nanoparticle fabrication [17-19], by linkage to 
the surface [20, 21], or by absorption on the surface after fabrication [22]. The use of 
each method depends on the chemistry of the therapeutic agent and the polymer, and 
the incorporation conditions [1, 23]. Depending on how the drug/bioactive molecule is 
contained, the entity is referred to differently. If the drug/bioactive molecule is located in 
a compartment surrounded by a polymer matrix, it is called a capsule. In the case that 
the molecule is dispersed in the polymer matrix, it is called a particle [1, 24]. Depending 
on the incorporation mechanism and the chemistry of the matrix polymer, the release 
 profiles may be different. When the drug is incorporated by loading in the fabrication 
method, the release profile depends on the erosion mechanism of the polymer and the 
size of the particle. A degradable polymer might undergo surface, bulk, or combined 
erosion profiles (Figure 2.2) [2, 25]
 
Figure 2.2 Release mechanisms.
compartment that contain the therapeutic agent surrounded by a matrix, called capsule (A), or 
from a dispersed state in the polymer, called particle (B), to the exterior. Biodegradable can 
degrade by two different mechanisms: Surface erosion (C) where the surface to degrade layer
by-layer, and bulk erosion (D) where water penetrates the device quickly allowing for the 
dissolution of the material. Initial time is represented by t=0 and a later time is re
Modified and adapted from Langer 
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 Diffusion is the main release mechanism either from a 
[2].  
-
presented by t’. 
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The release profile differs depending on the erosion mechanism. When solvent 
(i.e., water at physiological conditions) penetrates into the matrix of the particle (bulk 
erosion), an increased ‘‘burst release’’ and usually a more rapid release kinetics is likely 
to occur [26]. Size is another important variable that affects the release of the drug or 
bioactive molecule from particles. Nanoparticles offer more surface area than 
microparticles, which provides more surface area for contact with water, and hence 
nanoparticles are more likely to aggregate [26].  
The rational design of a drug delivery device includes the selection of the 
chemistry of polymer, not only to determine release profiles, but also for safety issues, 
since there are concerns about the safety of certain degradable polymers because high 
concentrations of degradation products might be toxic or cause instabilities to the 
therapeutic agent incorporated into the particle [24]. Biocompatibility is a term that has 
evolved from the understanding of an biological inert material to a material that interacts 
with the biological environment in an appropriate or beneficial manner depending on the 
specific application [27]. In particular, for the design of vaccines, the biocompatibility of 
the polymeric material and the degradation products is a very important characteristic in 
order to design not just effective, but safe formulations. For the rational design of 
vaccines, an in-depth understanding of biocompatibility is needed as the interaction of 
the material with its biological surroundings may result in immunomodulatory or 
adjuvant characteristics, but should not cause toxic effects on the host. The selection of 
polymers for rational vaccine design should take into consideration these 
characteristics.  
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2.2.2 Microparticles and nanoparticles 
The selection of the particle size is important depending on the specific 
application. Size has an important effect on the fate of the particle. Usually 
nanoparticles distribute more rapidly through the body (independent of the route of 
administration), but are more rapidly cleared as well; in contrast, microparticles tend to 
stay where they are placed [28-30]. For example, studies have shown that slow-
degrading microparticles were found at the site of infection after more than 8 weeks; in 
contrast, nanoparticles were cleared completely in the same time [31]. However, 
nanoparticle clearance can be prevented or delayed by reducing nonspecific distribution 
and targeting specific tissues or cell receptors by incorporating targeting ligands 
(peptide, aptamer, antibody, carbohydrates and other small molecules) [32]. 
Nanoparticles are more effective traveling through capillary regions and the respiratory 
track. This characteristic is useful to target specific organs such as lymph nodes or liver 
[33, 34], or for specific applications like intranasal administration [35, 36] or brain 
delivery [37, 38]. The diffusion of the drug is also affected by the particle size. 
Presumably, a greater proportion of drug can leave the surface of drug-loaded 
nanoparticles (which are smaller entities than microparticles) by diffusion [26]. 
2.2.2.1 Fabrication and characterization methods 
There are several fabrication methods of particles depending on the desired size 
(microparticles vs. nanoparticles). The most commonly used techniques for 
microparticle fabrication include hot-melting, emulsion solvent extraction, phase 
separation, and spray draying or atomization [39]. Methods for nanoparticles fabrication 
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are classified in two main groups: phase separation and solvent evaporation and 
chemical reactions including polymerization and polycondensation [15].  
Microparticles and nanoparticles are characterized in terms of their morphology, 
size distribution, and ζ-potential by photon correlation spectroscopy (PCS) or dynamic 
light scattering (DLS). Briefly, a monochromatic light is directed through a suspension of 
particles in Brownian motion. When the light hits a particle it causes a Doppler shift, 
changing the wavelength of the incoming light. The change in wavelength is related to 
the size of the particle [40]. A modified method from PCS is nanoparticle tracking 
analysis (NTA) by NanoSight Ltd. This technique includes an ultramicroscope and 
computer software that tracks particles movements and estimates their hydrodynamic 
radius, using the Stokes-Einstein equation [41]. In addition, electron microscopy 
techniques including scanning electron microscopy (SEM), transmission electron 
microscopy (TEM) and surface probe microscopy techniques such as atomic force 
microscopy (AFM) are commonly used to characterize particle morphology, surface 
roughness, and size distribution [41]. For SEM analysis, the sample must be a dry 
powder coated with a conductive metal to visualize the surface of the particles from the 
secondary electrons emitted. TEM is a technique that is very time consuming during the 
preparation of the sample, because the samples must be ultrathin and deposited onto 
grids. AFM is capable of imaging non-conductive material mounted on a sharp probe, 
so further preparation of the material is not required after mounting on probe [41].  
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2.2.2.2 Applications 
Extensive research has been conducted to develop effective delivery systems 
based on biodegradable polymers for drug delivery and vaccine formulations among 
other biomedical applications. Hydrolytically degradable polymers that have been used 
for biomedical applications include polyesters, polyurethanes, polyanhydrides, 
polyethers, polyphospoester, polyamides, and polycarbonates. Enzymatically 
degradable polymers include: proteins and poly(amino acids) (e.g. collagen, elastin, 
albumin, fibrin)  and polysaccharides (e.g. chitosan) [42] (Figure 2.3). Table 2.1 
presents an overview of representative applications for some of the most commonly 
investigated biodegradable polymers. A particular application relevant to the work 
herein is the use of biodegradable polymer based particles for intranasal vaccine 
design. The more relevant polymers for this application are discussed in Section 2.2.3.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 2.3 Chemical structure
applications. Hydrolytically degradable polymers include: polyesters (a), 
polyurethanes (b), polyanhydrides (c), polyethers (d), 
(f), polycarbonates (g). Enzymatically degradable polymers include: proteins such as 
collagen (h) (peptide bond structure is presented at the right of a three
structure of collagen) and polysaccharides such as ch
 
 
  
17 
s of commonly used polymers for biomedical 
polyphospoester (e), polyamides 
itosan (i). 
 
-dimensional 
18 
 
 
Table 2.1 Biodegradable polymers and their most representative applications 
 
Biodegradable polymers Representative applications References 
Synthetic polymers 
  
 Polyesters 
Poly(glycolic acid), poly (lactic acid) and 
copolymers 
Drug delivery, vaccine design, 
tissue engineering, gene 
delivery and barrier membranes. 
 
[43-48] 
Polyanydrides 
Poly[1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane] (CPTEG), poly[1,6-bis(p-
carboxyphenoxy) hexane] (CPH), 
poly(sebacic acid) (SA), poly(fumaric 
acid) (FA), 1,6-bis(carboxyphenoxy) 
hexane (MCPH) and copolymers  
 
Drug delivery, vaccine design 
and orthopedic applications. 
[19, 49-52] 
Polyethers  
Poly(ethylene glycol) (PEG) and 
poly(propylene glycol) (PPG) 
As modification on proteins and 
devices for pharmaceutical 
industry, drug delivery and gene 
delivery.  
[49, 53-55] 
Other synthetic polymers 
  
Poly(alkylcyanoacrylates) Adhesives, drug delivery [56-58] 
Polycarbonates Drug delivery [59] 
Polyamides Drug delivery [60] 
Polyurethanes Medical devices [61] 
Natural polymers 
  
Collagen Drug delivery, artificial skin, 
tissue engineering, and coating 
to improve cellular adhesion or 
guide tissue regeneration 
 
[45, 62-66] 
Fibrogen Tissue sealant 
 
[67, 68] 
Cellulose Wound healing device, tissue 
engineering 
 
[69, 70] 
Chitosan Drug delivery, vaccine design, 
tissue engineering 
[71-73] 
 
 
2.2.3 Controlled delivery of intranasal vaccines 
There are just a few vaccine adjuvants currently in the market that are approved 
for human use. It is evident that a critical need exists for novel immunomodulators and 
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potentiators, as well as delivery vehicles with the ability to trigger an effective humoral, 
cellular and mucosal immune response [74]. Recently, the development of potential 
delivery candidates for intranasal vaccines has gain relevance. Even though most of the 
currently available vaccines are injected systemically with few exceptions (i.e., oral 
vaccines against polio and Salmonella and the intranasal vaccine against influenza) 
[75], research on the design of intranasal vaccines has grown enormously. This is 
because of the ability of mucosal vaccination to induce both local and systemic 
immunity [76]. 
A variety of polymeric particles have been considered as vaccine delivery 
vehicles; however, very few of them have been studied for the design of intranasal 
vaccines. The most commonly investigated polymers are polyesters, polyanhydrides 
and chitosan. The size of particulate systems has an important effect on the distribution 
of particles in the respiratory track after an intranasal administration. Larger particles are 
trapped in the nasal cavity or upper respiratory track, while smaller particles have the 
capability to distribute in the lower respiratory track and even reach alveoli [77, 78]. 
Nanoparticles with a diameter between 100 and 500 nm are most efficient in passing 
through the nasal cavity into the lungs [79].  
Vaccination strategies might vary from forming a depot in the nasal cavity, from 
where the release of antigen can generate an immune response favoring antigen 
transport to the nasal-associated lymphoid tissue (NALT) to targeting particles to 
relevant immune cells like alveolar macrophages located in a deeper location in the 
respiratory track where the transport to bronchus-associated lymphoid tissue (BALT) is 
favored [80]. A comparison of the efficacy of both strategies has not been investigated, 
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and studies have been limited to antibody titer evaluation after administration of 
microparticles and nanoparticles in which contradicting results are available. Some 
authors have reported no significant difference between sizes [81, 82] and other reports 
show a clear effect of particle size [83, 84].  
In terms of chemistry, nanoparticles modified with carboxyl, sulfate, or amidine 
groups have a slow transport across mucosal surfaces; among these groups, the fastest 
transport was achieved by the most hydrophilic surface (i.e. amidine) [85]. The slow 
transport across the mucosal surface is a disadvantage, because such particles can be 
cleared from the mucosal tract [86]. Other studies have shown that particles with high 
amounts of low molecular weight polyethylene glycol  (PEG) on their surface improved 
the transport of nanoparticles by three orders of magnitudes [87]. Several authors have 
explained that PEG chains may establish an adhesive interaction due to their ability to 
inter-diffuse with the mucus network and form hydrogen bonds [86]. As stated before, 
the effectiveness of these carriers as intranasal vaccine delivery systems depends on 
the interaction of the particles with the mucosal surface, the recognition and uptake by 
relevant immune cells (i.e. alveolar macrophages), and the controlled release of the 
antigen in an active form, with the purpose of eliciting a more potent and long lasting 
immune response [88].  
2.2.3.1 Polyesters 
The chemical structure of polyesters is shown on Figure 2.3 A. Polyesters are 
degradable polymers, which have been approved by the U.S. Food and Drug 
Administration (FDA) for particular applications in humans (i.e., sutures, vaccine and 
drug delivery) [89]. Some of the specific polyesters that have been studied for vaccine 
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delivery applications include poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), 
poly(3-hydroxybutyric acid) (P3HB), poly(4-hydroxybutyric acid) (P4HB), and poly(ε-
caprolactone) (PCL) [90]. Polyesters exhibit biodegradability, controlled release 
capacity, and biocompatibility [91-93].  
In particular, PLGA and PLA have been investigated for their capabilities to be 
used as intranasal vaccine delivery vehicles. Contradictory results have been reported 
in the performance of PLA particles eliciting a proper immune response after intranasal 
administration. Some reports show an enhancement in immunoglobulin G and/or A (IgG 
and/or IgA) titers after administrations [94, 95], while others report poor performance of 
PLA particles alone [35, 96, 97]. An improvement in their performance has been 
reported when used PEG-PLA particles have been used [35, 97]. PEG has the ability to 
neutralize charge on the particles, increase hydrophilicity, and enhance particle diffusion 
in mucus [98]. PLGA microparticles have shown a potent induction of systemic and 
mucosal immunity after intranasal administration [99, 100]. However, their acidic 
degradation products are a major concern for the stability of antigens [101, 102]. In 
addition controlling antigen release kinetics is difficult since they erode by bulk erosion 
mechanism (Figure 2.2), which rapidly releases the encapsulated antigen. The ratio of 
glycolic acid to lactic acid determines the erosion rate, but high levels of glycolic acid 
increases crystalline domains in the polymer, which reduces its solubility in 
toxicologically acceptable solvents [103].  
2.2.3.2 Polyanhydrides  
Figure 2.3 C shows the chemical structure of polyanhydrides. This class of polymers 
is hydrolytically degradable and FDA has approved a polyanhydride-based device for 
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drug delivery to humans [104]. The surface erosion mechanism (Figure 2.2) is 
characteristic of polyanhydrides, which enables well-controlled drug/antigen release 
kinetics that can be modified by the chemistry of the polymer [105, 106]. In addition, the 
biocompatibility of the polyanhydrides and their degradation products has been reported 
[107-109] and a wide range of payloads can be encapsulated into these materials [110].  
Polyanhydrides have been used as drug delivery platforms, including vaccine 
delivery systems [19, 50, 52, 111-113]. Moreover, polyanhydride microparticles and 
nanoparticles have been shown to be capable of stabilizing proteins and sustain their 
release [114-116]. As published previously, polyanhydride particles made of copolymers 
of sebacic acid (SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) have 
immunomodulatory behavior in vivo [52]. In addition, a novel monomer, 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG), has been copolymerized with CPH to 
engineer amphiphilic environments to improve the stability of encapsulated proteins 
[116]. In addition, the environment due to the degradation products does not experience 
drastic changes in pH [117]. Recently, polyanhydrides were found to elicit Th1 
responses by acting as agonists for Toll-like receptors (TLRs) 2, 4 and 5 [113].  
However, few studies have exploited the use of polyanhydrides as intranasal vaccine 
delivery vehicles and adjuvants. The 50:50 CPTEG:CPH copolymer has been used 
successfully in the design of an single-dose intranasal vaccine against Yersinia pestis 
[19]. In addition, some studies suggest that anhydride chemistries enhance the 
transport of particles on mucosal surfaces. A study shows that PLGA/polyanhydride 
microspheres enhanced the nasal delivery of a drug when compared with PLGA 
microspheres alone [118]. Others have shown that polyanhydride nanoparticles (i.e., 
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FA:SA copolymer) could be absorbed across rat PP and normal intestinal epithelia 
[119]. This suggests their potential use as effective vaccine delivery systems, but further 
studies should be performed, such as the interaction of these polymers with relevant 
immune cells (as addressed in this thesis) as well as their biodistribution after an 
intranasal administration.  
2.2.3.3 Chitosan 
Chitosan (Figure 2.3 I) is a polysaccharide that has also shown significant 
promise as a degradable vaccine delivery vehicle. Its degradation is mediated by papain 
enzyme and the biocompatibility of the polymer and degradation products has been 
demonstrated [120-123]. It has been widely used as a nasal delivery vehicle that elicits 
high levels of IgG and IgA titers [124-128]. However, some studies report that the 
immune response elicited is more dependent on the route of delivery due to its 
mucoadhesive properties than its adjuvant properties [90, 129]. For example, intranasal 
delivery of N-trimethyl chitosan loaded with diphtheria toxoid enhanced the immune 
response over alum-based vaccines [130]. Nonetheless, Mohanan et al. [131] showed a 
sensitive immune bias in mice when vaccinated through subcutaneous, intradermal, 
intramuscular, and intralymphatic routes with ovalbumin-loaded N-trimethyl chitosan 
nanoparticles.  
2.3 Engineering intranasal vaccines: Immunological aspects 
2.3.1 Introduction 
The design of effective vaccines is a complex challenge that has gained 
importance over the past three decades [132]. Vaccines available in the market have 
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been developed empirically, with no profound understanding on how they active the 
immune system [133]. As stated by Plotkin [134, 135], the efficacy of current vaccines is 
based on the induction of protective antibodies, or an antibody-mediated immunity. This 
concept includes components such as high antibody titers or high amount of antibodies, 
antibody avidity, which refers to the quality or functional characteristics of antibodies, 
and antibody persistence or generation of memory B cells. However, other elements are 
crucial for many infectious diseases (e.g., HIV, malaria, tuberculosis, influenza) that 
require the induction an integrated induction of T cell memory as well as antibody-
mediated immunity [132]. The important role of B cells in vaccine efficacy should be 
integrated to an effective T cell response [136].The synergy of these two immunities is a 
complex challenge that is under investigation and has been conceptualized as vaccine-
mediated immunity [137]. New studies focus on understanding how adjuvants or 
antigens are recognized by the immune system and how they prime effector cells and 
antibodies for more efficient design of protective vaccines [133]. 
Even though there is growing interest in vaccine development and research, the 
optimal immune parameters (e.g. cytokine secretion, cell surface marker expression, 
antibodies titter, CD4 or CD8 T cell propagation) that are associated with an effective 
vaccine-mediated immunity remain unclear. Some authors have categorized immune 
responses observed as absolute correlates, relative correlates, co-correlates or 
subrogates to a vaccine when they provide near 100% protection, provide protection 
usually, provide protection in a species dependent manner, or does not provide 
protection, respectively [137]. New methods and techniques have emerged to assess 
immune parameters and their relationship with vaccine-mediated immunity such as 
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advances in flow cytometry [138], measure of cytokine production [139, 140], evaluation 
of T cell-dendritic cell interactions [141], assessment of macrophage phagocytosis and 
uptake [142, 143], among others.  
The development of these new technologies has acquired relevance together 
with the emergence of new methodologies to determine the safety of effective vaccines 
[133, 144]. Novel antigens have been proposed in order to overcome safety and 
efficacy challenges, including recombinant proteins [145-147], purified [148, 149] and 
synthetic [150, 151] microbial antigens, and DNA and RNA molecules [152-154]. 
Complementing the urgency to improve the safety and efficacy of vaccines, the 
discovery and design of vaccine adjuvants has been a key element and novel adjuvants 
have been investigated [155, 156]. Adjuvants enhance antigen-specific responses when 
they are co-administered with the antigen to elicit early, more potent, and long-lasting 
immune response [157, 158]. In addition, adjuvants can be used to reduce the amount 
of antigen and/or number of immunizations needed to generate a proper immune 
response, to improve the vaccination efficiency in newborns, elderly or immune-
compromised persons, or as delivery systems to target antigen presenting cells (APC) 
[159]. An “ideal adjuvant” is one that ensures biocompatibility (prevention of toxic 
effects), that can be manufactured consistently, that elicits a protective immune 
response with fragile antigens, and that preserves the immunogenicity of the antigen 
[160]. An additional desirable function is that an adjuvant can serve as immune 
modulator and controlled delivery vehicle.  
The design of effective adjuvants should not be a “mix and match” strategy that 
combines antigens and adjuvants, but requires a deep understanding of how innate and 
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adaptive immunities are connected. In this regard, the rational selection of specific 
adjuvants and specific antigens for particular diseases strongly depend upon the 
desired immune response. In addition, for the design of intranasal vaccines, the study of 
lung immunity is essential.  
2.3.2 From innate to adaptive immune response 
Immune memory is the capability of rapid activation and response of the immune 
system upon re-exposure of the host to a pathogen. Indeed, this is the very foundation 
of vaccination [161, 162]. Vaccination is the administration of an antigen to stimulate the 
immune system to trigger an adaptive immunity to a specific disease and elicit immune 
memory. An antigen is a particular molecule that binds specifically to an antibody; 
however an antigen may or may not have the ability to generate an immune response 
by itself. Particular antigens with this capability are called immunogens [158]. 
Immunity involves both specific and nonspecific components and can be broadly 
categorized into adaptive immunity and innate immunity. Adaptive immunity includes T 
and B lymphocytes its main characteristics are specificity (recognition of very precise 
antigens) and memory [158]. Innate immunity is considered to be a nonspecific 
response, with the capability of discriminating between pathogens and self-antigens. It 
comprises of phagocytic cells among other first-line of defense (e.g. natural killers, 
granulocytes, complement system) cells [158, 163]. The activation of the innate immune 
response is needed for the activation of adaptive immunity [163-166]. 
 As explained by Janeway [158], the innate immune system triggers an adaptive 
response in a series of steps. Briefly, antigen is encountered by APCs and is taken up 
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and internalized by several mechanisms (Figure 2.4), which have been described 
previously [167-169]. In general, depending on the antigen/pathogen size, chemistry, 
chemical patterns on its surface, or opsonization of antibodies, it is engulfed and 
processed either in endosomes or in cytosol. It is also possible that after destabilization 
of endosome, the antigen is released into the cytosol. Then the antigen is presented on 
the surface of APCs by major histocompatibility complex class I (MHC I) when 
processed in the cytosol or by class II (MHC II) when processed in endosome. Cross-
presentation pathways can also be activated (both MHC I and MHC II). APCs migrate 
from the periphery to lymphoid organs, where antigen presented in MHC I activates 
CD8+ T cells, and antigen presented in MHC II activates CD4+ T cells. In order to 
activate T cells, co-stimulatory signals are need, such as the expression of co-
stimulatory molecules on the surfaces of APCs (i.e. CD40, CD86, CD80), the release of 
pro-inflammatory cytokines (e.g. IL-1β and TNF-α), and the production of other 
cytokines that tailor the immune response (e.g. IL-12, IL-10, and IL-17). Subsequently, 
CD8+ T cells can become cytotoxic T cells (CTLs) and CD4+ cells become T helper cells 
1 or 2 (Th1 or Th2) depending on the cytokine signals provided by the APC. CTLs kill 
virally infected cells and tumor cells, Th1 assists in the activation of CTLs, and Th2 
assists B cells so that antibodies can be produced against the particular antigen (Figure 
2.5). 
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Figure 2.4 Uptake of antigens by antigen presenting cells. There are several endocytosis 
mechanisms that APCs use to uptake and internalize antigens/pathogens [167-169]. 
Phagocytosis (engulfment of large entities) includes receptor mediated endocytosis that 
comprises the internalization upon recognition through pattern recognition receptors (PRRs) (i.e. 
toll like receptors or TLRs, and C-type lectin receptors or CLRs). Macropinocytosis refers to the 
engulfment of small entities. 
  
  
 
 
Figure 2.5 Innate and adaptive immune response. 
antigen (A), which it is taken up and internalized by several mechanisms (B). After processing, the antigen is presented on t
surface of APCs (C) to T cells including CD4+ 
(D), while CD4+ cells become T helper cells 1 or 2 (Th1 or Th2) (E). 
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The innate immune system triggers an adaptive response by encountering an 
and CD8+. After antigen recognition, CD8+ T cells can become cytotoxic T cells (CTLs) 
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2.3.3 Lung immunity 
Two aspects drive the progress of “pathogen-mimicking” strategies: drug 
formulation and route of administration; both are key elements for the efficient design of 
vaccines. In particular, for vaccines against respiratory pathogens, intranasal 
administration mimics the entry of pathogens into the organism. It has been published 
that intranasal immunization has provided local and systemic robust immune responses 
against respiratory pathogens [170-174], which makes it an attractive route for the 
development of new vaccines. In particular, for the design of respiratory vaccines, the 
transport of particles across mucosal surfaces is crucial [175] and particle size and 
chemistry are important characteristics to improve transport efficiency [79, 85-87]. 
Pathogens can be mimicked by incorporating elements to the vaccine formulation that 
will lead the immune system sense danger signals similar to the actual infection [176]. A 
profound understanding of the respiratory tract immunity is needed so that a rational 
strategy can be formulated for the efficient design of vaccines.  
The respiratory tract is usually classified into two main parts, the upper and the 
lower zones. The upper respiratory tract comprises the nasal cavity, pharynx, and 
larynx. The lower respiratory tract includes trachea, primary bronchi, and lungs [177].  
The protection of lungs is associated with a series of anatomical barriers that vary 
through the tract, including mucociliary apparatus, enzymes, secretory IgA, and 
phagocytic cells that are constantly sensing the environment in order to detect the 
presence of pathogen [178]. After pathogen recognition, it is cleared and/or transported 
to draining lymph nodes [178].  
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The mucosa-associated lymphoid tissues (MALT) are dispersed aggregates of 
organized lymphoid tissue within the mucosa; which are responsible of mucosal-surface 
immune responses [179]. MALT includes pulmonary, nasal and gut associated 
lymphoid-tissue and together are known as the largest mammalian lymphoid organ 
system [180]. The bronchus-associated lymphoid tissue (BALT) and the nasal-
associated lymphoid tissue (NALT) are capable of generating T and B cell responses to 
inhaled antigens. BALT is located at bifurcations of the bronchus and it is present since 
the fetus development, and it matures after birth. NALT is located in the nasal passage 
and develops after birth [80]. Isotype switching of naive B cells to IgA and differentiation 
of T cells to Cytotoxic T cells (CTL) has been demonstrated on both BALT and NALT 
[181, 182], confirming that both cellular and humoral immunity can be triggered from this 
lymphoid tissues. Naïve B and T cells arrive to MALT via high endothelial venules [183, 
184]. Then, antigens are presented to the naïve T cells by APCs after intracellular 
processing. Furthermore, luminal antigens may be taken up and presented by B 
lymphocytes and epithelial cells to subsets of T lymphocytes [183]. Subsequently, naïve 
B cells are activated to become effector or memory cells. It is common that isotype 
switching occurs directly or sequentially (via IgG) to IgA. In fact, MALT structures are 
remarkable generators of IgA and J-chain expression (needed for its secretion) [158, 
184].  
Novel adjuvants have been used to target APCs from which an innate immune 
response can be initiated, subsequently eliciting an adaptive response. Much research 
has focused on the activation of DCs in order to elicit an immune response. However, 
depending on the type of vaccine, other APCs might play a principal role in eliciting 
32 
 
robust immune responses. In the respiratory tract, especially in the alveoli in the deep 
pulmonary region, alveolar macrophages (AM) have special relevance as the first line 
of immune defense. An interesting finding, relevant to the design of intranasal vaccines, 
is described by Kirby et al. [185] in which it was observed that >80% of cells obtained 
from bronchoalveolar lavage (BAL) were identified as AM. These studies showed that 
AM not only have a greater probability to encounter pathogens in the respiratory tract, 
but also that AM were the first cells to transport pathogen to the lung draining lymph 
nodes [185]. This suggests that AM are in charge of the connection between the 
innate and the adaptive immune response in lung immunity transporting antigens to the 
BALT and its activation is relevant when vaccines are design to target the lower 
respiratory tract.  
2.3.4 Macrophages  
Macrophages (M) are white blood cells produced by the differentiation of 
monocytes in tissues [158]. According to Mosser and Edwards, there is a full spectrum 
of M that share some characteristics, but actually play different functions going from 
classically activated, regulatory, to wound healing [186]. In particular, Hume [187] has 
stated that classical activated M perform similar functions as DCs and even have a 
greater potential to present antigen to T cells due to their higher propensity to take up 
antigen. The APCs described as “professional” include macrophages, Langerhans cells, 
and dendritic cells (i.e. myeloid and lymphoid DCs), but B cells can also perform 
professional presentation of antigens [188, 189].  
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An abundant population of M is contained in most tissues (up to 15% of total 
cells) [190-192], which generates several phenotypes depending on the tissue. The 
plasticity of these cells is remarkable. In addition, its phagocytic activity is extremely 
high even in the absence of inflammatory signals. The process of phagocytosis per se 
enables the presentation of the antigens; their exposure to specific cytokines and 
danger signals up-regulates the expression of co-stimulatory signals that contribute to 
prime and amplify the response of T cells [193]. In addition, other functions are 
conferred to M, such as chemotaxis, phagocytosis and pathogen killing, clearance of 
dying and dead cells,  tumor-cell control, and secretion of immune modulators and 
enzymes (e.g. nitric oxide, proteases, cytokines, reactive oxygen intermediates, 
coagulation factors, etc.) [193].  
Alveolar macrophages (AM) are the major defense cells in the lung playing an 
important role in inflammation, control of infection and antigen transport to draining 
lymph nodes [185, 194, 195]. In addition, their important role as regulatory cells, 
managing the homeostasis of the lung, is fundamental. AM have the capability to 
direct suppressive signals [196, 197]. This implies that the rational design of intranasal 
vaccines has to take in consideration the homeostatic role of AM, so that vaccine-
induced signals can elicit a potent immune response and not tolerance. AM are 
equipped with receptors to recognize foreign, altered-self, and self-components [198]. In 
fact, AM recognize danger invaders by recognizing pathogen-associated molecular 
patterns (PAMPs) thought pattern recognition receptors (PRRs). Toll-like receptors 
(TLRs) and C-type lectin (CLRs) are important PRRs that recognize widely distributed 
structures in pathogens. Particularly, CLRs recognize carbohydrate structures, which 
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are extensively expressed on the surface of respiratory pathogens. CLRs are 
considered a key component of the immunity in lungs [199]. 
2.4 Targeted vaccine design 
2.4.1 Introduction 
Efficient vaccines should be engineered to mimic an infection, in order to provide 
protective immunity to disease, but without the undesirable effects of the pathogen. A 
pathogen can be mimicked by non-infectious materials in several aspects; for example, 
using the route that the pathogen uses to infect the host, and providing elements that 
can be recognized by immune cells as foreign [200, 201]. The use of biodegradable 
particles as adjuvant/delivery vehicles can be enhanced by targeting strategies, which 
can improve the delivery of the payload to particular tissues or cells and overcome 
biological barriers, as well as provide appropriate danger signals to elicit a robust 
immune response.  
Targeting strategies can be classified in two broad groups: passive and active 
[202-204].  Passive targeting strategies are focused on changing particle size and 
chemistry to achieve higher delivery efficiency. Active strategies are oriented to target 
specific cells or tissues, using ligands on the surface of particles that bind to specific 
receptors, or antibodies for a higher specificity in the binding of the receptor. The latter 
strategy will be discussed in this section, since passive targeting strategy was 
discussed in Section 2.2.  
It is important to highlight that appropriate targeting depends on the specific 
application of the vaccine. Although vaccines have been understood as prophylactic 
strategies, the development of novel vaccines has changed this concept. Currently, 
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therapeutic vaccines have been investigated as a method to activate the immune 
system against illnesses such as cancer and HIV/AIDS [205-207]. In particular, the 
targeting of Mƙ plays an important role in the development of therapeutic vaccines, 
because of their ability to inhibit replication of intracellular parasites, tumor growth, and 
induction of an immune response [208]. However, the aim of this section is to illustrate 
immune targets and targeting strategies for the specific purpose of designing a 
prophylactic vaccine against pathogens.  
2.4.2 Antigen presenting cells as immune targets 
Targeting specific receptors is an interesting strategy in the rational design of 
novel adjuvants. It is an effective strategy to enhance uptake and internalization of 
antigenic or genetic materials by APCs. In fact, a wide distribution of PRRs could be 
immune targets with the potential to tailor the immune response. PRRs include Toll-like 
receptors (TLRs), NOD-like receptors, RIG-I-Like Receptors (RLRs), and C-type lectin 
receptors (CLRs) [209-211].  
Vaccination strategies include the modification of antigen as well as 
functionalization of surface particles, both employing targeting agents. The potential of 
functionalized polymer particles with specific ligands that can be recognized by PRRs is 
enormous for the development of novel adjuvants. Several researchers agree that 
targeting PRRs allows a more specific, efficient and less toxic response [165, 166, 212-
218] that has the capability to “shape” the immune response [164, 165, 209, 210].  
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2.4.2.1 C-type Lectin Receptors 
CLRs are excellent targets when the purpose is to trigger the innate response 
because of their high expression by APCs and endocytic properties. The regulatory role 
of the innate response and the triggering of adaptive immune responses through the 
effector function of APCs usually requires the collaboration of other PRRs, i.e. TLRs 
[219]. CLRs perform various functions, such as cell adhesion/migration, tissue 
integration, pathogen recognition and internalization (i.e., endocytosis, phagocytosis), 
cell activation and immune induction and modulation, etc. [220]. It is important to state 
that depending on the binding properties of the antibody or ligands, immune response, 
tolerance or suppression can be generated [216, 218, 221].  
Despite the existence of a wide range of CLRs with similar or overlapping ligand 
specificity, each receptor appears to have distinct functions depending on the context in 
which the ligand is recognized [222]. Figure 2.6 shows some of them with their 
respective ligands and function.  
 
 Figure 2.6 C-type lectin receptors. 
representative as well as the known biological outcome after cross
presented in this figure. In particular, DEC205 has several carbohydrate recognition domains, 
but has been targeted using antibodies, since its carbohydrate ligand remains unknown. 
 
2.4.2.2 Toll-Like Receptors
Toll-Like Receptors (TLRs) recognize different molecules ranging from 
lipopolysaccharides to nucleic acids, and the synergy between them is singula
Three of the most important TLRs are TLR 2, TLR 4 and TLR 9 because of their 
function in modulating the im
glycolipids and lipopolysaccharides. Its activity is determined by the interaction with 
other TLR such as TLR6 (recogn
main ligand is lipoprotein). TLR2 by itself does not induce cytokine production, but it 
does after the interaction with activated TLR6 or TLR1 
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r [158].  
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TLR4 recognizes lipopolysaccharide (LPS) which is an integral component of the 
outer membrane of gram negative bacteria [158]. In humans, TLR4 is not activated 
upon the only recognition of LPS, suggesting that an additional molecule is required for 
downstream signaling [165]. In fact, it is known that TLR4 is a signaling receptor, but not 
the LPS uptake receptor. The LPS uptake mechanism is still unknown [223].  
The recognition of bacterial DNA is attributed to TLR 9 [158]. Certain bacterial 
oligonucleotides that contain unmethylated nucleotides can stimulate APCs because of 
their recognition through TLR9. However, eukaryotic DNA and methylated 
oligonucleotides are not recognized by this receptor. After recognition of the ligand, the 
receptor is stimulated and cells express co-stimulatory molecules, increase antigen 
presentation, and produce Th1 signature cytokines (i.e. IL-12 and IL-18). The strong 
Th1 response induced suggests that it is a promising target in the design of adjuvants 
for vaccines against a wide variety of infectious agents and cancer antigens [165]. 
Characterization of the TLR signaling pathways is a strategy that leads to the 
comprehension of the mechanism that links recognition of pathogens and the resultant 
immune response.  
2.4.3 Targeting strategies 
Numerous strategies have been studied for the active targeting of receptors with 
an eye towards generation of potent immune responses. Strategies include, but are not 
limited to, antibody-mediated targeting and the direct modification of antigens and/or 
particles with specific ligands. 
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2.4.3.1 Antibody-mediated targeting 
Antibody-targeted vaccines take advantage of the high affinity of antibodies to 
recognize specific molecules. This strategy has been used for the treatment of cancer, 
using monoclonal antibodies that recognize specific tumor antigens, in order to direct 
the delivery of chemotherapy drugs and tumor-growth inhibitors [224, 225]. These 
monoclonal antibodies recognize specific cytokines and molecules that promote 
angiogenesis and tumor growth, with the purpose to inhibit them [226, 227]. This is an 
example of the design of therapeutic vaccines in which the activation of immune 
response is directed to cancer cells. In addition, antibodies have been used to target 
receptors to which a specific ligand remains unknown (e.g. DEC205) [228, 229]. 
Moreover, monoclonal antibodies have been used to target specific markers of immune 
cells in order to direct cargo. Particular receptors of cells, such as CD11b or CD11c, 
have been used to target particular APCs, resulting in a high antibody titer response, 
suggesting a successful delivery to APCs [230, 231]. 
2.4.3.2 Functionalization of antigens and particles  
This strategy might include the use of antibodies [228, 232] and small molecules 
(e.g. saccharides, amino acids) [233, 234] chemically bonded to antigens or particles 
with the aim to direct its delivery to immune cells, or provide a directed response 
depending on the ligand. The applications of these strategies include the activation of 
the immune response against cancer cells or foreign pathogens. Specially, antigens that 
have been modified with targeted agents are still challenged in terms of their 
immunogenic properties and the incorporation of an adjuvant is needed. The use of 
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polymeric devices not only as delivery vehicles, but also as immunomodulators has 
helped overcome this problem. The functionalization of the surface of these delivery 
vehicles provides the opportunity to exploit active targeting strategies. The approach 
includes the conjugation of different molecules, including antibodies, peptides, and 
carbohydrates, low-molecular weight polymers, etc. that confer the capability to target 
specific cells, receptors or tissues, or modification of surface chemistry to improve 
particle interaction with biological environment. This allows the delivery of the payload in 
a directed manner [235-239]. Results show the outcome of the strategy depends on the 
particular immune target and the strategy used, and its rationale depends on the 
specific application. For example, Copland et al. [240] showed improved internalization 
of mannosylated liposomes by DCs. Another strategy is the linkage of synthetic 
peptides to the surface polymeric particles. Studies show the in vitro efficacy of 
nanoparticles targeting neurons using tetanus toxin C fragment (TTC) as ligand [241, 
242]. The strategies herein presented are an exciting opportunity to improve the design 
of targeted vaccine platforms. 
2.5 Conclusions 
Biodegradable polymeric particles are promising carriers of poorly immunogenic 
antigens (i.e. recombinant proteins, nucleic acids, etc.) that preserve their stability and 
antigenicity. In particular, polyanhydride nanoparticles offer unique characteristics for 
the design of vaccines including controlled release of the antigen, biocompatibility, 
protein stability, and immunomodulatory properties. Previous studies have shown the 
potential of polyanhydride nanoparticles to be used as carriers for intranasal vaccines. 
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The use of nanoparticles (100-500 nm in diameter) as vaccine carriers is an interesting 
strategy because these particles can be distributed throughout the respiratory tract, 
including alveolar regions. AM are one of the most important immune cells in the 
respiratory tract and play a key role in translating an innate stimulation to a long lasting 
adaptive response, transporting antigens to BALT. AM are armed with PRRs, which 
sense pathogens and initiate signaling pathways to trigger an immune response. In 
particular, C-type lectin receptors are predominant elements of lung immunity and 
targeting CLRs may be a viable strategy for the design of efficacious intranasal 
vaccines. 
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CHAPTER 3: RESEARCH OBJECTIVES 
3.1 Overall Research Goal  
The overall goal of this project is to design a targeted nanovaccine platform by 
functionalizing the surface of amphiphilic polyanhydride nanoparticles to target specific 
C-type lectin receptors (CLRs). In this work, we have evaluated the capacity of these 
targeted nanoparticles to get internalized by and activate alveolar macrophages, and 
through mechanistic studies with knockout mice, we have shown that the specific 
engagement of CLRs plays an important role in their recognition. The results will 
provide valuable insights in the development of intranasal vaccine formulations. This 
study focuses on amphiphilic polyanhydrides based on 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) and 1,6-bis(p-carboxyphenoxy)hexane (CPH). The saccharides 
used to modify the surface of CPTEG:CPH nanoparticles are di-mannose and 
galactose. 
3.2 Specific Goals 
The specific goals of the project are: 
Specific goal 1: High throughput synthesis and characterization of functionalized 
polyanhydride nanoparticles. 
Specific goal 2: Design of functionalized polyanhydride nanoparticles to target C-type 
lectin receptors on alveolar macrophages. 
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CHAPTER 4: HIGH THROUGHPUT SYNTHESIS AND CARBOHYDRATE 
MODIFICATION OF POLYANHYDRIDE NANOPARTICLES  
 
4.1 Abstract 
The rational design of vaccine carriers has integrated several characteristics 
such as a rational selection of polymer, chemistry, incorporation of various antigens and 
targeting agents. High throughput fabrication and modification of biomaterials is a 
powerful tool that increases the ability to study a wide array of devices. In addition, 
automated set ups increase the reproducibility of the procedures. LabView® platform 
was used to operate a series of three pumps and five different actuators that allowed 
the automated high throughput synthesis of polyanydride copolymers, nanoparticle 
fabrication, and surface modification by attaching carbohydrates. This last procedure 
was optimized by varying the temperature and the total reaction time. Optimal 
conditions permitted the efficient surface functionalization of nanoparticles, maintaining 
their morphology and a consistent carbohydrate concentration on their surface.  
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4.2 Introduction  
The use of computational software platforms to operate laboratory equipment is a 
powerful tool to improve the accuracy and throughput of diverse processes. LabVIEW® 
(National Instruments, Columbus, OH) is a visual programming tool that can manage 
various pieces of equipment and perform calculations for a more effective research 
activities [1]. Its standardized use allows for different research laboratories to replicate 
published procedures by reducing troubleshooting and building up knowledge.  
Automated high-throughput strategies for the fabrication or modification of biomaterials 
enhance the feasibility of constructing consistent and reproducible devices that integrate 
several desirable characteristics. 
The integration of different features on delivery carriers is acquiring renewed 
importance in the rational design of biomaterials for numerous applications. The 
variation of parameters such as chemistry [2-5], erosion mechanisms [5-8], size or 
geometry to target specific cells [9-12], and the incorporation of targeting agents [13-15] 
has been studied. Increasing the throughput in the fabrication method to unearth the 
complexities associated with such a multi-parametric system will be of great value.  
In vaccine design, polyanhydride nanoparticles offer controlled release of the 
payload (i.e., antigen) that can be tailored by changing the chemistry of the polymer. 
Due their hydrophobic chemistry, these polymers experience surface erosion through 
hydrolytic degradation. By modifying the hydrophobicity of the polymer via 
copolymerization with different anhydride monomers, controlled release can be 
achieved, allowing for tailored degradation ranging from days to months [16-18]. In 
addition, the stabilization of novel antigens has been achieved by introducing 
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amphiphilic chemistries [8, 16, 17, 19].  Finally, these materials exhibit adjuvant and  
immunomodulatory properties [20], making them promising candidates as vaccine 
adjuvants.  
The addition of a targeting ligand capable of being recognized by specific 
receptors on immune cells has been studied [21] to selectively trigger an immune 
response. C-type lectin receptors (CLRs) are pattern recognition receptors (PRRs) that 
recognize carbohydrates present on the surface of pathogens. The stimulation of 
immune cells via CLRs allows for the internalization of antigen and subsequent 
presentation for further T cell activation; in addition, tyrosine motifs located on their 
transmembrane tails permits downstream signaling [22-25].  
In this work, the development of a high throughput procedure for functionalization 
of polyanhydride nanoparticles employing an automated robotic set up operated by 
LabView® is described. Temperature and reaction time were the parameters employed 
to optimize the process, to achieve consistent nanoparticle morphology with a 
reproducible carbohydrate concentration on the nanoparticle surface.  
4.3 Materials and Methods 
4.3.1 Materials  
The chemicals needed for monomer synthesis, polymerization and nanoparticle 
fabrication include 1,6-dibromohexane, triethylene glycol, 4-p-hydroxybenzoic acid, and 
1-methyl-2-pyrrolidinone; these were purchased from Sigma–Aldrich (St. Louis, MO); 4-
p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); toluene, sulfuric 
acid, acetonitrile, dimethyl formamide, acetic anhydride, methylene chloride, pentane, 
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and potassium carbonate were obtained from Fisher Scientific (Fairlawn, NJ); p-carboxy 
benzoic acid (99+%), and 1-methyl-2- pyrrolidinone, anhydrous (99+%), were 
purchased from Aldrich (Milwaukee, WI). For 1H NMR characterization deuterated 
chemicals including chloroform and dimethyl sulfoxide were purchased from Cambridge 
Isotope Laboratories (Andover, MA).  
4.3.2 Monomer and high throughput polymer synthesis  
The 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) monomers were synthesized as previously described [26, 
27]. Using a modified version of the automated robotic apparatus (Figure 4.1) described 
previously [3, 4, 8], 50:50 CPTEG:CPH copolymer was synthesized. Briefly, two single-
syringe pumps NE 1000 (New Era Pump Systems, Farmingdale, NY) were connected in 
series; each pump contained a 10 mL glass syringe (Hamilton, Reno, NV) loaded with 
each pre-polymer dissolved in acetic anhydride (15 mg/mL) and connected to 24 in. 
stainless steel capillaries. Pumps were used to infuse desired amount of prepolymers 
into glass cuvettes. Tips were held on a clamp mounted on a robotic stage with 
movement in the x and y direction. Glass cuvettes were placed on a metal rack 
mounted on a robotic stage with movement in the x, y and z directions. Robotic stages 
were built using automated actuators (Zaber Technologies, Vancouver, British 
Columbia, Canada) connected in series, one for each direction. Pumps and actuators 
were connected to a computer and the robotic apparatus was operated using 
LabVIEW®. Prepolymer at the appropriate concentration was polymerized at 0.3 torr 
vacuum and 140°C. Copolymer films were obtained after  polymerization. Discrete 
libraries ranging from homopolymers (CPH or CPTEG) to copolymers of various 
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compositions were synthesized using this setup of the deposition apparatus and 
compared to results from conventional syntheses [3].  The current studies are focused 
on a single chemistry (i.e., 50:50 CPTEG:CPH). 
 
 
Figure 4.1 Schematic representations of robotic deposition apparatus. The automated 
deposition apparatus consists of (A) three NE 1000 pumps; (B) a robotic stage integrated by two 
actuators (Zaber) one for movement in the x direction and another one for movement in the y 
direction; (C) a second robotic stage with two adjacent racks (appropriate for tubes and 
cuvettes) consisting of three actuators one for each direction (x, y, and z). The pumps were and 
a total of five actuators were connected in series. Actuators and pumps were operated by a 
computer using LabVIEW® software. This diagram is not to scale. 
 
4.3.3 Nanoparticle Fabrication 
A nanoprecipitation technique was adapted and used from previous work [11]. 
The precipitation of nanoparticles into an anti-solvent was performed utilizing the 
automated robotic set up shown in Figure 4.1. First, cold methylene chloride (-20°C) 
was loaded into a glass syringe and deposited into glass cuvettes to dissolve 50:50 
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CPH:CPTEG copolymer at a concentration of 25 mg/mL using one of the pumps. A 
second pump was used to deposit cold pentane (-30°C) into  glass test tubes, held on an 
adjacent rack mounted on the stage with movement in the x, y, and z directions. A third 
pump was used to withdraw the dissolved polymer from the cuvettes (at 4 mL/min) and 
dispensed into test tubes containing pentane (at 7.5 mL/min). Instant precipitation of 
nanoparticles was observed. The ratio of methylene chloride:pentane was optimized at 
1:200. Nanoparticles were filtered or centrifuged (depending on the batch size) to 
remove pentane and dried overnight in a vacuum chamber.  
4.3.4 Surface functionalization 
The rationale for the selection of each specific ligand is shown in Figure 4.2. 
Deprotected saccharides were synthesized by Dr. Nicola Pohl's group in the Chemistry 
Department at ISU. Deprotected lactose, di-mannose, or galactose were conjugated on 
the surface of polyanhydride nanoparticles by an amine-carboxylic acid coupling 
reaction [21], which was optimized by varying reaction times and temperatures. Briefly, 
the process consisted of two consecutive reactions. For the first reaction, one pump 
was loaded with a gas-tight glass syringe containing 12 equivalents (eq.) of 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 10 eq. of ethylene diamine 
per 100 mg of nanoparticles in an aqueous solution. A second pump was loaded with a 
syringe containing 12 eq. of N-hydroxysuccinimide (NHS) per 100 mg of nanoparticles 
in aqueous solution. A nanoparticle suspension was obtained after deposition and 
incubated at two different temperatures (4°C and 25° C) at a constant agitation using a 
rotoshaker (Scientific Industries, Bohemia, NY). Nanoparticles were washed twice by 
centrifuging (10,000 rpm for 5 min) and adding nanopure water and sonicating at 40 Hz 
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for 30 s. For the second reaction, two deposition steps were used. In the first deposition 
step, 12 eq. of EDC were loaded with one pump, 12 eq. of NHS with the second pump 
per 100 mg of particles. A third pump was employed for 10 eq. of glycolic acid (used for 
the control groups, since deprotected saccharides already have this molecule covalently 
linked to the saccharide). The second deposition step included 10 eq. of each 
saccharide on each pump (i.e., galactose, lactose or di-mannose). Each saccharide was 
deposited into test tubes depending on the desired group. The nanoparticle suspension 
was incubated at 4°C and 25°C with constant agitation.  The times of both reactions 
were varied as shown in Table 4.1. Preliminary studies showed that same temperature 
was optimal for both reactions and that the second reaction was more responsive to 
changes in time (data not shown). The nanoparticles were washed once as described 
previously and dried under vacuum for 6 hours.  
 
 
 
 
  
Figure 4.2 Rational design of 
attached to the surface of 50:50 CPTEG:CPH nanoparticles. In the chemical structures shown, 
carboxylic acids present on the surface of polyanhydrides and the ethylene diamine group that 
serves as a linker are represented; (A) shows the chemical structures of the deprotected di
mannose functionalized nanoparticles, which were designed as a potential ligand for the 
macrophage mannose receptor (MMR), which recognizes mannose residues and CIRE which 
recognizes highly mannosylated structures. (B) shows galactose functionalized nanoparticles, 
which were designed as a potential ligand for the macrophage galactose lectin (MGL) receptor 
that recognizes galactose residues as well as N
functionalized nanoparticles, which do not serve as a specific ligand for any particular receptor. 
 
 
Table 4.1 Reaction times used to optimize amine
Total reaction time (h) 
4 
6.5 
9 
13.5 
18 
21 
24 
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functionalized nanoparticles. Three saccharide groups were 
-acetyl galactosamine. (C)
-carboxylic acid coupling reaction
First reaction time (h) Second reaction time (h)
2 2 
2 4.5 
4.5 4.5 
4.5 9 
9 9 
9 12 
12 12 
 
-
 shows lactose 
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4.3.5 Polymer and nanoparticle characterization 
The chemical structure of the copolymer was characterized with 1H NMR with a 
Varian VXR 300 MHz spectrometer (Varian Inc., Palo Alto, CA). Deutorated chloroform 
was used to dissolve the polymer and the spectra were calibrated with respect to the 
chloroform peak (δ=7.26 ppm). The molecular weight was determined using gel 
permeation chromatography (GPC) using a Waters GPC chromatograph (Milford, MA)  
containing PL gel columns (Polymer Laboratories, Amherst, MA) and elution times were 
compared to monodisperse polystyrene standards (Fluka, Milwaukee, WI). Particles 
were characterized by scanning electron microscopy (SEM, FEI Quanta 250) and 
dynamic light scattering (DLS, Zetasizer Nano, Malvern Instruments Ltd., Worchester, 
UK) evaluating their morphology, size and ζ-potential. A high throughput phenol sulfuric 
acid assay previously described [21, 28] was used to quantify saccharide concentration 
on nanoparticles surface.  
4.4 Results and Discussion 
4.4.1 Translation of operational software 
Previous work from our laboratories [3, 8, 9, 29-31] described a similar robotic 
set up as the one shown in Figure 4.1. In that work, a fixed stage and a mobile stage in 
x, y, and z directions was operated by a third party software that integrated the 
information from the pumps and actuators. The addition of a second movable stage 
increased the throughput and reduced the time for each process (i.e., prepolymer 
deposition and nanoparticle precipitation). The translation of the operation of stages and 
pumps to LabVIEW® improved the ease of use of the set up as well as the 
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reproducibility of the process, since each process was programmed in a standard 
manner so that the user can change parameters as flow rate, batch size, concentration, 
etc. without changing the program code. As shown in Figure 4.3, the program has a 
user-friendly interface and a visual programed code. The user interface allows for the 
input of several parameters that are easily incorporated into the program code. The 
environment offered by the visual programming language is user-friendly and permits 
the rapid identification of sources of error.  
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Figure 4.3 Example screenshot of a typical polyanhydride synthesis program. LabVIEW®  
permits the visual programming of robotic setups through a visual diagram flow (A). Each 
program can be standardized for a process asking for specific information per run to the user 
using a user-friendly interface in which images, buttons, etc. can be added (B). 
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4.4.2 Synthesis of polymer and fabrication of nanoparticles 
A 50:50 CPTEG:CPH random copolymer was synthesized as described 
previously [5]. The molecular weight (Mw) of the copolymer was 8,000 g/mol and 1H 
NMR spectra of the copolymer were consistent with previously published data [5, 9, 31]. 
The nanoparticles were fabricated using the robotic set up described in Figure 4.1.  It 
was shown that when filtration was used as the separation method to remove pentane 
in the nanoparticle precipitation, less particle aggregation (average diameter =163 ± 24 
nm) was observed. The yield of nanoparticles by filtration was ~50% for small-size 
batches (10-25 mg), while for larger batches the yield improved to ~85%. The yield by 
centrifugation was consistent (>90%) for both small and large batch sizes. Filtration was 
employed for large batches for the fabrication of nanoparticles used for functionalization 
since the functionalization process did not result in aggregated nanoparticles. 
4.4.3 Effect on nanoparticle morphology 
 The effect of reaction temperature and time on nanoparticle morphology 
was profound, which is consistent with the fact that biodegradable polyanhydrides are 
hydrolytically labile. A qualitative assessment was performed by comparing 
representative SEM images of particles synthesized under different reaction conditions. 
It was observed that cold temperatures and short reaction times improved the 
morphology of the nanoparticles, preventing aggregates. In addition, the copolymer is 
greatly affected by the long incubation times in aqueous solution, leading to an 
investigation of the reduction of total reaction time. Aggregation of particles was 
observed at early stages of the reaction when the reaction was carried out at room 
temperature. The cold temperature helped delay the onset of aggregation to ~9 h of 
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total reaction time. Figure 4.4 shows the morphology of four experimental groups at 
longer total reaction times (i.e., 18 h and 24 h) at 4°C and 25°C. These 
photomicrographs show the detrimental effect of longer reaction times on the 
nanoparticle morphology and size. These results confirm that thermal properties of the 
materials such as the glass temperature (Tg) are important in their processability and 
morphology. It has been reported that the Tg of 50:50 CPTEG:CPH is 8°C [5]. The 
biodegradability and phase behavior of the copolymer is another important factor to 
consider. Specifically, 50:50 CPTEG:CPH is an amorphous copolymer, which would 
lead to faster erosion rates compared to, for example, poly(CPH), which would degrade 
more slowly and is semi-crystalline [5].  
4.4.4 Effect on saccharide concentration 
In the process of optimization of the amine carboxylic acid coupling reaction, the 
concentration of saccharide on the surface of nanoparticles is very important. The effect 
on saccharide concentration was studied by varying temperature and reaction time as 
shown in Figure 4.5. At cold temperatures and shorter total reaction times, the surface 
concentration of saccharides was lower in comparison to those of reactions carried out 
at room temperature. The differences in the concentration of the saccharides were less 
significant when comparing reactions carried out at 4°C  and 25°C at longer total 
reaction times. The concentration of saccharides at longer reaction times did not vary 
greatly, when compared to the variability observed from 4 to 18 h of total reaction time 
at both temperatures.  
 
 
71 
 
 
 
 
 
  
 
Figure 4.4 Morphology of nanoparticles at different reaction conditions. SEM images show 
the effect of temperature (4°C and 25°C) and total reaction time (18 h and 24 h) on the 
morphology of glycolic acid functionalized 50:50 CPTEG:CPH nanoparticles. Scale bar 5 µm.  
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Figure 4.5 Effect of reaction conditions on saccharide concentration. (A) Di-mannose, (B) 
Lactose and (C) Galactose.  In these experiments, 50:50 CPTEG:CPH nanoparticles were used 
at different reaction times and temperatures: 4°C ( ) and 25°C ( ). The average and standard 
error of three independent functionalization experiments is shown. 
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4.4.5 Optimized conditions 
In summary, optimal conditions for functionalizing 50:50 CPTEG:CPH 
nanoparticles were found to be 18 h of total reaction time at 4°C. Under these 
conditions, reasonable and reproducible surface concentrations and spherical particle 
morphologies were observed. Figure 4.6 shows representative SEM images of each 
functionalization; in all cases, aggregation was reduced by sonication. The results of the 
nanoparticle characterization are summarized in Table 4.2. The non-functionalized 
nanoparticles showed a negative ζ-potential, which is characteristic of carboxylic acid 
motifs present on the surface of nanoparticles. After ethylenediamine was covalently 
linked to the nanoparticles (by the first reaction), the ζ-potential changes to a positive 
value; this is expected because of the amine groups present on the surface of the 
particle. Glycolic acid functionalization or linker control showed a less positive surface 
charge. All the saccharide-functionalized nanoparticles also showed positive surface 
charge, indicating partial coverage of the particle surface by the saccharides. This 
observation is consistent with the surface coverage of the particles as shown in Figure 
4.6.  
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Figure 4.6 Optimized morphology and surface functionalization of nanoparticles. 
Chemical structures of functional groups as well as SEM images of 50:50 CPTEG:CPH 
nanoparticles: (A) Non-functionalized, (B) Ethylenediamine, (C) Glycolic acid, (D) di-mannose, 
(E) lactose, and (F) galactose. Scale bar = 5 µm.  
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Table 4.2 Characterization of functionalized nanoparticles 
Nanoparticle group Average diameter 
(nm) 
ζ-Potential 
(mV) 
Saccharide 
concentration 
(ng/cm2) 
Non-functionalized 163 ± 24  23 ± 2.5  N/A 
Ethylenediamine 263  ± 34  31 ± 3.6  N/A 
Glycolic acid 261 ± 44  20 ±  2.7  N/A 
Di-mannose 271 ± 40  28 ± 1.7 4.8 ±  0.3 
Lactose  268  ± 51  26 ± 1.3 5.8 ±  0.7 
Galactose 263 ± 44  24 ± 2.8 5.2 ±  0.4 
N/A indicates “not applicable”.  
4.5 Conclusions 
A standardized high throughput methodology for the surface functionalization of 
polyanhydride nanoparticles was developed in which specific parameters were varied to 
build discrete libraries of functionalized nanoparticles. Several programs were 
developed on the LabVIEW® platform for polymer synthesis, nanoparticle fabrication, 
and nanoparticle functionalization in order to improve the ease and reproducibility of the 
process by different users. The visual programming language provided a useful tool to 
automate pumps and actuators. The increased throughput and reduction of process 
time afforded by the robotic set up enabled the rapid optimization of the functionalization 
of polyanhydride nanoparticles with respect to reaction temperature and total reaction 
time. The systematic study showed that 4°C and a total reaction time of 18 h were 
optimal conditions that resulted in spherical nanoparticles with equivalent concentration 
of saccharide attached to the surface. This methodology is reproducible, reduces batch 
to batch variability and user error, and allows for its use in further in vivo and in vitro 
studies for various applications. The methodology could also be extended to 
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functionalize nanoparticles with proteins, nucleic acids, other types of sugars such as 
high-mannosylated structures, glucan, etc., to enable research on targeting other PRRs 
(e.g., TLRs), cancer cells, or specific tissues.  
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5.1 Abstract 
C-type lectin receptors (CLRs) offer unique advantages for tailoring immune 
responses. Engagement of CLRs regulates antigen presenting cell (APC) activation and 
promotes delivery of antigens to specific intracellular compartments inside APCs for 
efficient processing and presentation. In these studies, we describe a novel approach to 
targeted antigen delivery by decorating the surface of polyanhydride nanoparticles with 
specific carbohydrates to provide “pathogen-like” properties. Two conserved 
carbohydrate structures often found on the surface of respiratory pathogens, galactose 
and di-mannose, were used to functionalize the surface of polyanhydride nanoparticles 
and target CLRs on alveolar macrophages (AM), a principle respiratory tract APC. Co-
culture of functionalized nanoparticles with AM significantly increased cell surface 
expression of MHC I and II, CD86, CD40 and the CLR CIRE over non-functionalized 
nanoparticles. Di-mannose and galactose functionalization also enhanced the 
expression of the macrophage mannose receptor (MMR) and the macrophage 
galactose lectin (MGL), respectively. This enhanced AM activation phenotype was 
found to be dependent upon nanoparticle internalization. Functionalization also 
promoted increased AM production of the pro-inflammatory cytokines IL-1ƙ, IL-6 and 
TNF-ƙ. Additional studies demonstrated the requirement of the MMR for the enhanced 
cellular uptake and activation provided by the di-mannose functionalized nanoparticles. 
These data indicate that targeted engagement of MMR and other CLRs is a viable 
strategy for enhancing the intrinsic adjuvant properties of nanovaccine adjuvants and 
promoting robust pulmonary immunity. 
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5.2 Introduction 
Acute respiratory infections cause 4.25 million deaths worldwide every year [1]. A 
critical need exists for the development of efficacious intranasal vaccines against 
respiratory pathogens capable of inducing robust and protective mucosal immunity. In 
this regard, there is growing interest in the development of vaccines that can be easily 
administered at the site of infection that elicit both local and systemic immune 
responses [2-5]. 
The study of alveolar macrophages (AM), a type of antigen presenting cell 
(APC) in the respiratory tract, is central to the development of intranasal vaccines. AM 
constitute more than 80% of the total cells obtained by bronchoalveolar lavage and they 
constitutively migrate from the lung to the draining lymph nodes (DLN) [6-8]. Indeed, 
AM containing bacteria appear in the lung DLN prior to the onset of pathogen-induced 
DC migration, thereby making them integral to the establishment of protective 
pulmonary immune responses [6]. AM are equipped to detect pathogens with the aid 
of pattern recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPs) [9]. One family of PRRs found on AM, known as C-type lectin 
receptors (CLRs), recognize conserved carbohydrate structures, including mannose 
and galactose, found on the surface of many respiratory pathogens, such as Yersinia 
pestis, Mycobacterium tuberculosis, Streptococcus pneumoniae and influenza viruses 
[10-14]. CLRs also function as phagocytic receptors and include members of the 
mannose receptor family and DC-SIGN (dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin) [15]. Depending on the specific CLR, ligand binding 
initiates downstream signaling cascades that promote immune cell migration to the DLN 
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as well as antigen processing and presentation via MHC I and/or MHC II to prime naïve 
T cells [16-20]. 
Several research groups have explored CLR targeting as a vaccine design 
strategy to ensure efficient delivery of cargo to intracellular compartments that facilitate 
antigen processing and presentation [21-29]. Many studies have demonstrated the 
effectiveness of using antibodies [22] or mannoproteins from pathogens [26] to target 
CLRs and activate APCs. However, only a limited number report the use of 
carbohydrate-functionalized vaccine carriers as part of an improved adjuvant for 
intranasal vaccines [21, 24]. Work published by Jiang et al. indicated that alveolar 
macrophages could recognize mannosylated chitosan microparticles when delivered 
intranasally [24]. Unfortunately, mechanistic studies demonstrating the engagement of 
the mannose receptor on AM by these particles were not performed. 
Here, we describe functionalization of polyanhydride nanoparticles with two 
conserved carbohydrate structures commonly found on the surface of respiratory 
pathogens, di-mannose and galactose. The addition of these carbohydrates significantly 
enhanced the intrinsic adjuvant activity of our polyanhydride nanovaccine platform by 
further upregulating AM surface expression of MHC I and II, CLRs, and T cell co-
stimulatory molecules as well as secretion of pro-inflammatory cytokines. Moreover, we 
demonstrate that di-mannose functionalized polyanhydride nanoparticles specifically 
engaged the macrophage mannose receptor in order to enhance nanoparticle uptake 
and activate AM. 
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5.3 Materials and Methods 
5.3.1 Materials  
The chemicals needed for monomer synthesis, polymerization and nanoparticle 
fabrication included 1,6-dibromohexane, triethylene glycol, 4-p-hydroxybenzoic acid, 
and 1-methyl-2-pyrrolidinone; these were purchased from Sigma–Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); toluene, 
sulfuric acid, acetonitrile, dimethyl formamide, acetic anhydride, methylene chloride, 
pentane, and potassium carbonate were obtained from Fisher Scientific (Fairlawn, NJ); 
p-carboxy benzoic acid (99+%), and 1-methyl-2- pyrrolidinone, anhydrous (99+%) were 
purchased from Aldrich (Milwaukee, WI). For 1H NMR characterization, deuterated 
chemicals, including chloroform and dimethyl sulfoxide, were purchased from 
Cambridge Isotope Laboratories (Andover, MA). 
5.3.2 Monomer and polymer synthesis 
The 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) monomers were synthesized as previously described [30, 
31]. Random copolymers with a 50:50 ratio of CPH and CPTEG were synthesized by 
melt polycondensation using an automated robotic deposition apparatus operated with 
LabVIEW® (National Instruments) as previously described [31-35]. The chemical 
structure of the polymers was characterized via 1H NMR with a Varian VXR 300 MHz 
spectrometer (Varian Inc., Palo Alto, CA). Deuterated chloroform was used to dissolve 
the polymer and spectra were calibrated with respect to the chloroform peak (δ=7.26 
ppm). The polymer molecular mass was determined using gel permeation 
chromatography (GPC). Samples were dissolved in HPLC-grade chloroform and 
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separated on a Waters GPC chromatograph (Milford, MA) containing PL gel columns 
(Polymer Laboratories, Amherst, MA) comparing elution times to monodisperse 
polystyrene standards (Fluka, Milwaukee, WI). 
5.3.3 High throughput synthesis of carbohydrates 
A robotic set up was used for the iterative synthesis of linear α-1,2-linked di-
mannose with a fluorous allyl group using fluorous solid phase extraction (FSPE) 
serving as a model to obtain the di-mannoside [21, 36-38]. Carboxymethyl – di-
mannose synthesis was performed by ozonolysis of the alkene [39] followed by further 
oxidation with Jones reagent [37]. Global deprotection under Birch reduction conditions 
[40] produced the fully deprotected α-1,2-linked di-mannose. In addition, β-1-O-allylated 
galactose was prepared from β-penta-O-acetylated galactose using allyl alcohol and 
BF3.OEt2. Eight equivalents of NaIO4 utilized under ruthenium-catalyzed Sharpless 
conditions [41, 42] produced the desired acid in 91% yield. Subsequent deacetylation 
under mild conditions using K2CO3 provided the desired fully deprotected galactoside. 
5.3.4 High throughput synthesis and characterization of functionalized 
nanoparticles 
The fabrication of functionalized 50:50 CPTEG:CPH nanoparticles was 
performed via an anti-solvent nanoencapsulation method using an automated robotic 
deposition apparatus operated by LabView® [32, 33, 43]. Galactose and di-mannose 
residues were conjugated to the surface of nanoparticles by a modified and optimized 
two-step amine carboxylic acid coupling reaction [21]. Briefly, the first reaction was 
performed at 4°C by incubating the nanoparticle suspen sion (100 mg/mL) with 12 
equivalents (eq.) of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
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(EDC), 12 eq. of N-hydroxysuccinimide (NHS), and 10 eq. of ethylenediamine in 
nanopure water for 9 h with constant agitation using a rotor shaker (Scientific Industries, 
Bohemia, NY). Nanoparticles were washed twice by centrifugation (10,000 rpm for 5 
min) with the addition of nanopure water and sonication (at 40 Hz for 30 s). The second 
reaction was performed at 4°C in a nanoparticle suspensio n (50 mg/mL) in nanopure 
water with 12 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding saccharide 
(i.e., galactose or di-mannose) or glycolic acid (linker between saccharide and 
nanoparticles; a control treatment for AM experiments) for 9 h with constant agitation. 
Nanoparticles were washed once and dried under vacuum for 6 h. The automated set 
up was used to accurately dispense solutions of EDC, ethylenediamine, and NHS for 
the first reaction, and solutions of EDC, NHS, and saccharides in the second reaction to 
increase the throughput of the process. Particle morphology was characterized by 
scanning electron microscopy (SEM, FEI Quanta 250, Kyoto, Japan), and 
hydrodynamic size and ζ-potential were determined by dynamic light scattering (DLS, 
Zetasizer Nano, Malvern Instruments Ltd., Worchester, UK). The saccharide 
concentration conjugated to the nanoparticles was measured using a high throughput 
phenol sulfuric acid assay as previously described [21, 44].  
5.3.5 Mice 
Wild type (WT) C57BL/6 (B6) mice were purchased from Harlan Laboratories 
(Indianapolis, IN) and macrophage mannose receptor deficient (MMR-/-) B6 mice were a 
generous gift from Dr. Mary Ann McDowell of the University of Notre Dame. Mice were 
housed in specific pathogen-free conditions where all bedding, caging, and feed were 
sterilized prior to use. All animal procedures were conducted with the approval of the 
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Iowa State University Institutional Animal Care and Use Committee. 
5.3.6 Cell harvesting and culture 
Murine alveolar macrophages (AM) from WT and MMR-/- B6 mice were 
harvested by bronchoalveolar lavage as previously described [6, 7, 45]. Briefly, mice 
were euthanized and a sterile catheter inserted into the trachea of each mouse. Using a 
1 mL syringe fitted with the catheter, 0.75 mL of room temperature, sterile PBS was 
gently infused into the lungs and then aspirated back into syringe. This process was 
repeated six times while externally massaging the chest. Following collection, lavage 
fluid was immediately placed on ice prior to centrifugation (250 x g, 10 min, 4°C). Cell 
viability was then assessed using trypan blue. Cells were cultured in Dulbecco's 
Modified Eagle Medium containing 4.5 mg of glucose/mL, 2 mM L-glutamine, 100 U 
penicillin, 100 µg streptomycin/mL, 25 mM HEPES and 10% fetal bovine serum in six-
well plates at a density of 5 x 105 cells/well for 8 h at 37°C and 5% CO 2. After 6 h of 
incubation, non-adherent cells were discarded and adherent cells (>90%) were 
incubated overnight prior to treatment. Non-functionalized or functionalized 
nanoparticles were incubated with AM at a concentration of 0.125 mg/mL. Non-
stimulated AM and AM stimulated with Escherichia coli lipopolysaccharide (LPS, 200 
ng/mL Sigma Aldrich, St. Louis, MO) were used as negative and positive controls 
respectively. After 48 h, supernatants were collected for quantification of cytokines and 
nitrites. Cells were stained for flow cytometric analysis.  
5.3.7 Cell surface marker evaluation 
Flow cytometric evaluation of cell surface markers was performed by modifying a 
previously described protocol [46]. Briefly, cells were washed in 2 mL of fluorescence-
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activated cell sorting buffer (FACS, 0.1% sodium azide and 0.1% bovine serum albumin 
in phosphate buffer saline). Fcγ receptors were blocked with 10% purified rat anti-
mouse CD16/CD32 antibody (BD Bioscience, San Diego, CA) in 1 mg/mL rat IgG for 30 
min at 4°C to prevent non-specific binding. AM were incubated with appropriate 
antibodies or isotype controls for 15 min on ice. Antibodies used for assessment of 
activation included phycoerythrin (PE)-Cy7 conjugated anti-mouse F4/80 (clone BM8), 
fluorescein isothiocyanate (FITC)-conjugated anti-mouse/rat MHC II (I-A/I-E, clone 
M5/114.15.2), allophycocyanin (APC) anti-mouse CD40 (clone 1C10) and PE 
conjugated anti-mouse MHC I (H-2Kb, clone AF6-88.5.5.3). These antibodies and their 
respective isotype controls were purchased from eBioscience (San Diego, CA). APC-
Cy7 anti-mouse CD86 (clone GL-1) was purchased from Biolegend (San Diego, CA). 
Antibodies used to evaluate CLR expression included F4/80, biotin conjugated anti-
mouse CD209 (clone 5H10) and PE-Texas red conjugated streptavidin purchased from 
BD Biosciences, FITC anti-mouse CD206 (MMR, clone MR5D3) purchased from 
Biolegend and PE-CD301a/b (MGL1/2, affinity purified PAb catalog # FAB4297P) 
purchased from R&D systems (Minneapolis, MN). Samples were acquired using a 
FACSAria III flow cytometer (BD Biosciences) and data was analyzed using FlowJo 
software (TreeStar Inc., Ashland, OR). 
5.3.8 Nanoparticle internalization 
Nanoparticles were loaded with cadmium selenide quantum dots (QDs; emission 
at 630 nm) prior to functionalization. The QDs were kindly provided by Dr. Aaron Clapp, 
Iowa State University. QD-loaded functionalized and non-functionalized nanoparticles 
were used to stimulate AM for 48h. Cells were then analyzed by flow cytometry to 
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identify the populations of nanoparticle-positive and nanoparticle-negative cells as 
described previously [47]. A QD control (background) was used to account for “false 
positives” because of QDs released due to particle degradation. QD-loaded 
functionalized and non-functionalized nanoparticles were incubated in cell culture media 
for 48 h. After centrifugation (250 x g, 10 min, 4°C), supernatants were added to AM. 
After 48 h, the fluorescence registered for these control groups was considered as 
background. Cells were labeled with the above-described F4/80, MHC II, CD40, CD86 
and CD301a/b antibodies as wells as with Pacific blue anti-mouse MHC I (H-2Kb, clone 
AF6-88.5) purchased from Biolegend, biotin anti-mouse CD209 and PerCP-Cy5.5 
conjugated streptavidin purchased from eBioscience. 
5.3.9 Cytokine and reactive nitrogen species assays 
After stimulation for 48 h with non-functionalized or functionalized nanoparticles, 
cell-free supernatants were assayed for IL-1β, IL-10, TNF-α, IL-6, and IL-12p40 using a 
multiplex cytokine assay in conjunction with a Bioplex 200 System (Bio-Rad, Hercules, 
CA) as described elsewhere [33]. Griess Reagent (Invitrogen, Carlsbad, CA) was used 
to determine nitrite concentration as an indirect method to measure reactive nitrogen 
species. 
5.2.11 Statistical analysis 
The statistical software JMP®7 was used to analyze all data. Tukey’s HSD was 
used to determine significant differences among treatments. A student’s T test was 
employed to determine the significant differences between AM harvested from WT 
versus MMR-/- mice and between nanoparticle positive and negative AM. All p values 
< 0.05 were considered significant.  
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5.4 Results 
5.4.1 Synthesis and characterization of functionalized polyanhydride 
nanoparticles. 
Amphiphilic 50:50 CPTEG:CPH copolymer was synthesized as described 
previously [31]. The molecular weight (Mw) of the copolymer was 8,000 g/mol and 1H 
NMR spectra of the copolymer were consistent with previously published data [31, 33, 
35]. Particle morphology was evaluated by SEM (data not shown). The average 
diameter of the non-functionalized nanoparticles was 163 ± 24 nm with a ζ-potential of -
23 ± 2.5 mV (consistent with the presence of carboxylic acids on the surface). The 
glycolic acid (linker only) functionalized nanoparticles had an average diameter of 261 ± 
44 nm and a ζ-potential of 20 ± 2.7 mV, while di-mannose functionalized and galactose 
functionalized nanoparticles had average diameters of 271 ± 40 nm and 263 ± 44 nm, 
respectively, with similar ζ-potentials of 26 ± 1.9 mV. The positive charges of the 
functionalized particles were consistent with previously published data [21] and are 
attributed to the presence of free ethylenediamine groups on the surface of the 
particles. Measuring the ζ-potential of ethylenediamine-functionalized nanoparticles 
(determined to be 31 ± 3.6 mV) further corroborated this result. These data indicate that 
partial capping of the ethylenediamine groups occurs when the saccharide is 
conjugated in the second reaction of the process. The di-mannose and galactose 
concentrations attached to the nanoparticles were normalized to the total mass of 
nanoparticles. The di-mannose concentration was 13.2 ± 3.5 µg/mg, consistent with 
previous work [21]. The galactose concentration conjugated to the nanoparticles was 
15.2 ± 4.7 µg/mg. 
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5.4.2 Functionalization of polyanhydride nanoparticles enhanced AM 
expression of MHC, T cell co-stimulatory molecules and CLRs. 
Previous works from our laboratories have highlighted the intrinsic adjuvant 
activity of polyanhydride particles, as evidenced by their ability to activate DCs [46, 47]. 
In the current study, we observe, for the first time, enhanced expression of surface 
markers associated with antigen processing and presentation (MHC I and II) and T-cell 
co-stimulation (CD86 and CD40) in primary AM cultured with non-functionalized 
polyanhydride nanoparticles as compared to non-stimulated AM (Figure 5.1A-D). 
Culture of AM with non-functionalized polyanhydride nanoparticles also enhanced 
surface expression of CLRs (MMR, MGL and CIRE) in comparison to non-stimulated 
AM and AM stimulated with LPS (Figure 5.1E-G). 
Functionalization of polyanhydride nanoparticles with either di-mannose or 
galactose provided a significant upregulation in the expression of MHC I and CD40 on 
the surface of AM in comparison to treatment with either non-functionalized particles 
or particles functionalized with only glycolic acid, the linker used to attach the 
carbohydrates to the nanoparticles (Figures 5.1A and 5.1D). AM MHC II and CD86 
expression were enhanced over non-functionalized particles regardless of the 
nanoparticle functionalization (Figures 5.1B and 5.1C), with the greatest enhancement 
in MHC II observed on AM cultured with di-mannose functionalized particles (Figure 
5.1B). As compared to non-functionalized nanoparticles, expression of the MMR on 
AM was only significantly enhanced upon culture with di-mannose functionalized 
nanoparticles (Figure 5.1E) while only culture with galactose functionalized 
nanoparticles significantly increased AM MGL expression (Figure 1F). No significant 
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enhancement in CIRE expression was observed when AM were cultured with 
functionalized versus non-functionalized nanoparticles (Figure 1G). 
Together, these observations indicate that carbohydrate functionalization of 
polyanhydride nanoparticles enhanced AM activation as compared to non-
functionalized particles. In some instances (for MHC II and CD86 expression), 
functionalization with only the glycolic acid linker increased AM activation, indicating 
that nanoparticle surface charge contributes to AM activation. Finally, AM culture 
with di-mannose or galactose functionalized particles provided enhanced cellular 
activation profiles that were comparable or even superior to those observed in AM 
stimulated with LPS. 
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Figure 5.1 Functionalization of polyanhydride nanoparticles enhanced AM expression 
of MHC, T cell co-stimulatory molecules and CLRs. After stimulation with non-functionalized 
(NF) or functionalized nanoparticles for 48 hrs, AM were harvested and analyzed by flow 
cytometry for surface expression of (A) MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MMR, (F) 
MGL, or (G) CIRE. LPS stimulated and non-stimulated cells (NS) were used as positive and 
negative controls, respectively. Data are expressed as the mean ± the SEM of three 
independent experiments performed in triplicate. Treatments with different letters are 
significantly different from one another at p < 0.05. MFI = mean fluorescence intensity. 
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5.4.3 Internalization of functionalized polyanhydride nanoparticles was 
required for upregulation of CD40 expression on AM 
Pathogen phagocytosis is an important step in activating macrophages [48, 49]. 
We therefore evaluated the relationship between nanoparticle internalization and AM 
activation using quantum dot-loaded nanoparticles and flow cytometry [47]. 
Internalization of, and not just association with, nanoparticles by AM was confirmed by 
confocal microscopy (data not shown). Two populations of cells were identified—cells 
that internalized QD-loaded nanoparticles (nanoparticle-positive) and cells that did not 
internalize particles (nanoparticle-negative). Internalization of nanoparticles, regardless 
of functionalization status, was found to be required for the enhanced expression of 
CD40 on AM (Figure 5.2B), but not for the expression of CD86, MHC I, and MHC II 
(Figure 5.2A and data not shown). 
Interestingly, the nanoparticle-positive cells that internalized di-mannose but not 
galactose-functionalized nanoparticles expressed significantly greater levels of the 
MMR on their surface as compared to nanoparticle-negative cells (Figure 5.2C). A 
similar relationship was observed for galactose but not di-mannose functionalized 
particles and MGL expression (Figure 5.2D). These data support an association 
between internalization of nanoparticles functionalized with a certain carbohydrate and 
the enhanced expression of the receptor specific for that carbohydrate. 
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Figure 5.2 Internalization of functionalized polyanhydride nanoparticles was required for 
upregulation of CD40 expression on AM. Percent of AM that internalized (nanoparticle-
positive; ) or did not internalize (nanoparticle-negative; ) nanoparticles after 48 hrs that were 
also positive for (A) CD86, (B) CD40, (C) MMR, (D) MGL, or (E) CIRE. Data are expressed as 
the mean ± the SEM of three independent experiments performed in triplicate. * represents a 
statistically significant difference between nanoparticle-positive and nanoparticle-negative 
populations within a treatment at p < 0.05. 
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5.4.4 Carbohydrate functionalization of nanoparticles differentially 
influenced proinflammatory cytokine secretion 
Previous reports from our laboratory have described the ability of non-
functionalized polyanhydride nanoparticles to enhance secretion of pro-inflammatory 
cytokines from APCs [32, 46]. In this present work, we sought to extend our findings by 
asking if functionalization with specific carbohydrates provides additional stimulatory 
capacity to the polyanhydride nanoparticles. Indeed, di-mannose functionalized 
nanoparticles significantly enhanced the production of IL-1β from AM as compared to 
all nanoparticle treatments (Figure 5.3A). Functionalization with either di-mannose or 
the glycolic acid linker but not galactose enhanced AM secretion of TNF-ƙ (Figure 
3B). Di-mannose modification of the nanoparticles provided no additional benefit in 
terms of enhancing IL-6 and IL-12p40 production (Figures 5.3C and 5.3D). Of note, 
functionalization with either the glycolic acid linker only or galactose diminished the 
enhanced IL-12p40 secretion observed when AM were co-cultured with non-
functionalized nanoparticles (Figure 5.3D). No IL-10 was detected in the supernatants 
of any AM and nanoparticle co-cultures (data not shown). 
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Figure 5.3 Carbohydrate functionalization of nanoparticles differentially influenced pro-
inflammatory cytokine secretion. After stimulation with non-functionalized (NF) or 
functionalized nanoparticles for 48 hrs, culture supernatants were harvested and assayed for 
(A) IL-1β, (B) TNF-α, (C) IL-6, and (D) IL-12p40. LPS stimulated and non-stimulated cells (NS) 
were used as positive and negative controls, respectively. Mean cytokine production for AM 
stimulated with LPS: IL-1β = 1,021.7 ± 66.5 pg/mL, IL-6 = 7,804.3 ± 101.2 pg/mL, TNF-α = 
5,711.5 ±181.7 pg/mL, and IL-12p40 = 3,637.8 ± 111.6 pg/mL. (F) Nitrate concentration was 
measured in culture supernatants via a Griess assay as an indirect method to quantify 
production of reactive nitrogen species. Data are expressed as the mean ± the SEM of three 
independent experiments performed in triplicate. Treatments with different letters are 
significantly different from one another at p < 0.05. 
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5.4.5 Di-mannose functionalized nanoparticles enhanced internalization 
and AM activation by engaging the macrophage mannose receptor. 
In Figure 5.2, we observed that nanoparticle internalization was required for 
increased CD40 and CLR expression. We next performed additional experiments to 
determine if the enhanced activation of AM by functionalized nanoparticles seen in 
Figures 5.1 and 5.3 was associated with enhanced nanoparticle internalization. Using 
quantum dot-loaded nanoparticles and flow cytometry, we found that any 
functionalization of the nanoparticle surface enhanced uptake by AM as compared to 
non-functionalized particles (Figure 5.4, white bars). 
To test the specificity of the di-mannose modification for binding to the MMR, we 
isolated AM from MMR-deficient (MMR-/-) mice and co-cultured them with 
functionalized nanoparticles. As compared to wild type (WT) AM, a significant 
decrease in the number of internalized nanoparticles was only observed when di-
mannose functionalized nanoparticles were co-cultured with MMR-/- AM (Figure 5.4, 
white versus black bars). These data indicate that di-mannose functionalized 
nanoparticles specifically interact with the MMR, while nanoparticles functionalized with 
galactose or only the glycolic acid linker are internalized via other, non-MMR-dependent 
pathways. Similar results were obtained using bone marrow-derived macrophages 
(BMMƙ; Supplemental Figure 5.1). 
Consistent with the internalization data, only the MMR-/- AM co-cultured with di-
mannose functionalized nanoparticles failed to enhance surface expression of MHC I, 
MHC II, CD86 and CD40 to levels consistent with those observed for WT AM (Figures 
5.5A – D). Similarly, MMR-/- AM only secreted significantly less IL-1β and IL-6 as 
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compared to WT AM when co-cultured with di-mannose functionalized nanoparticles 
(Figures 6A and 6C). As compared to WT AM, reduced levels of CIRE expression 
(Figure 5E) and TNF-ƙ and IL-12p40 secretion (Figures 5. 6B and 5.6D) were also 
observed in MMR-/- AM co-cultured with di-mannose functionalized as well as with 
non-functionalized nanoparticles. The absence of the MMR had no negative effect on 
the increased surface marker expression and cytokine production observed when AM 
were co-cultured with galactose functionalized nanoparticles (Figures 5.5 and 5.6), 
indicating that galactose functionalized particles do not engage the MMR to promote 
AM activation. Similar observations were made using BMM (Supplemental Figures 
5.2 and 5.3). Together, these data support the concept that di-mannose functionalized 
nanoparticles enhance AM activation by specifically engaging the MMR. 
 
 
Figure 5.4 Di-mannose functionalized nanoparticles enhanced internalization by 
engaging the macrophage mannose receptor on AM. Percent of wild type () and MMR-
deficient (MMR-/-; ) AM that internalized nanoparticles after 48 hrs. Data are expressed as 
the mean ± the SEM of three independent experiments performed in triplicate. * represents a 
statistically significant difference between wild type and MMR-/- AM within a treatment at p < 
0.05. # represents a statistically significant difference from the non-functionalized nanoparticle 
treatment group for wild type AM. 
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Figure 5. Di-mannose functionalized nanoparticles enhanced AM expression of MHC, T 
cell co-stimulatory molecules and CLRs by engaging the macrophage mannose receptor. 
After stimulation with non-functionalized (NF) or functionalized nanoparticles for 48 hrs, wild 
type () and MMR-deficient (MMR-/-; ) AM were harvested and analyzed by flow cytometry 
for surface expression of (A) MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. 
Data are expressed as the mean ± the SEM of three independent experiments performed in 
triplicate. * represents a statistically significant difference between wild type and MMR-/- AM 
within a treatment at p < 0.05. MFI = mean fluorescence intensity. 
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Figure 6. Di-mannose functionalized nanoparticles enhanced AM pro-inflammatory 
cytokine production by engaging the macrophage mannose receptor. After stimulation with 
non-functionalized (NF) or functionalized nanoparticles for 48 hrs, culture supernatants from 
wild type () and MMR-deficient (MMR-/-; ) AM were harvested and assayed for (A) IL-1β, 
(B) TNF-α, (C) IL-6, and (D) IL-12p40. Non-stimulated cells (NS) were used as a negative 
control. Data are expressed as the mean ± the SEM of three independent experiments 
performed in triplicate. * represents a statistically significant difference between wild type and 
MMR-/- AM within a treatment at p < 0.05. 
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5.5 Discussion  
In the present work, we describe a novel approach to targeted antigen delivery 
by decorating the surface of polyanhydride nanoparticles with specific carbohydrates to 
provide “pathogen-like” properties that ensure nanoparticles engage C-type lectin 
receptors on AM to induce robust immune responses in the respiratory tract. The 
surface of polyanhydride nanoparticles was functionalized by covalent linkage of di-
mannose and galactose residues. Co-culture of functionalized nanoparticles with AM 
significantly increased cell surface expression of MHC I and II, CD86, CD40 and the C-
type lectin receptor CIRE over non-functionalized nanoparticles (Figures 5.1A-D and 
1G). Di-mannose and galactose functionalization also enhanced the expression of the 
MMR and MGL, respectively (Figures 5.1E and 1F). Carbohydrate modification also 
significantly increased uptake of the nanoparticles by AM. Moreover, the enhanced 
expression of CD40, CIRE, MMR and MGL on AM cultured with functionalized 
nanoparticles was found to be dependent upon nanoparticle internalization (Figure 5.2). 
In addition, functionalization promoted increased AM production of IL-1ƙ, IL-6 and 
TNF-α. Additional studies demonstrated the requirement of the MMR for the enhanced 
cellular uptake and activation provided by the di-mannose functionalized nanoparticles 
(Figure 5.4-5.6). 
Di-mannose and galactose functionalized nanoparticles were engineered with an 
eye towards targeting specific receptors such as CIRE, MMR, and MGL. Our results 
show that the targeting of these specific receptors, known for their ability to internalize 
antigens and present them in MHC I and/or MHC II compartments [50-52], resulted in a 
higher percentage of cells that internalize nanoparticles (Figure 5.4, open bars). This 
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enhanced internalization may improve antigen delivery to AM and result in the 
enhancement of the expression of activation markers (i.e., MHC I, MHC II, CD86, and 
CD40) as shown in Figure 5.1. Our studies also evaluated the relationship between 
nanoparticle internalization and cell surface marker expression (Figure 5.2A and 5.2B). 
Simply the presence of the nanoparticles in the co-culture was sufficient for 
enhancement of certain activation markers (i.e. CD86, MHC I, and MHC II), while 
internalization was required for the expression of other activation makers, including 
CD40. 
Nanoparticle internalization also played a critical role in the enhanced expression 
of CLRs (Figures 5.2C-E). MMR expression was enhanced on AM following co-
culture with mannose-functionalized nanoparticles (Figure 5.1E), and this enhanced 
expression required internalization of the nanoparticles (Figure 5.2C). Similar results 
were observed for MGL (Figures 5.1F and 5.2D). The expression of the CIRE receptor 
was enhanced by most of the nanoparticle groups, but only cells that internalized non-
functionalized and di-mannose functionalized nanoparticles showed enhanced 
expression of this marker (Figures 5.1G and 5.2E). Several reports have shown that 
CLRs undergo internalization and recycling between the plasma membrane and the 
endosomal compartments [53-55]. Our results suggest the presence of a feedback loop 
that increases the expression of these markers after ligand recognition. 
The production of pro-inflammatory cytokines is essential for the activation of 
macrophages as initiators of an adaptive immune response [56]. Di-mannose 
functionalization enhanced the production of IL-12p40, IL-1β and TNF-α (Figures 5.3A-
D). These results are in agreement with studies demonstrating that the targeting of 
104 
 
MMR resulted in the production of pro-inflammatory cytokines through the activation of 
NF-ƙB [57]. Although the production of pro-inflammatory cytokines was enhanced by 
the di-mannose functionalization, the levels secreted were low enough to allay concerns 
about a chronic inflammation event in the respiratory tract. The galactose functionalized 
nanoparticles resulted in an enhanced production of cytokines in comparison with the 
negative control, but at lower levels than the non-functionalized nanoparticles, 
particularly for IL-12p40. The release of pro-inflammatory cytokines when the cells were 
treated with galactose-functionalized particles showed was similar to that of the non-
functionalized nanoparticles. Previous studies suggest that galactose motifs enhanced 
the production of cytokines such as IL-12p40 and TNF-α, but not to the levels obtained 
when mannose motifs are used [57, 58]. 
The constant production of reactive nitrogen species is related to chronic 
inflammation and cancers of several organs, including lungs [59]. Such a response may 
be needed to combat an infection; however it would not be desirable in an intranasal 
vaccine. As shown in Figure 5.3E, all the nanoparticle groups have similar levels of 
reactive nitrogen species production in comparison with the non-stimulated group 
(negative control). Together, these data demonstrate that di-mannose functionalization 
significantly enhanced the expression of cell surface makers and the production of 
relevant cytokines. These events could promote a suitable phenotype of AM that could 
trigger an enhanced T cell activation, which is an important outcome for intranasal 
vaccines.  
To further assess the engagement of MMR in the specific recognition of di-
mannose functionalized nanoparticles, studies were performed on AM harvested from 
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MMR KO mice. Statistically significant differences were observed in the internalization 
of di-mannose functionalized nanoparticles between AM harvested from wild type and 
MMR KO mice (Figure 5.4), indicating that the enhanced uptake observed when 
polyanhydride nanoparticles are functionalized occurs via MMR-mediated endocytosis. 
Enhanced uptake was also seen for glycolic acid functionalized nanoparticles as 
compared to non-functionalized nanoparticles. This may be attributed to the hydrophilic 
properties conferred by the mannose and glycolic acid groups to the surface of the 
particles that may increase their internalization in comparison to more hydrophobic 
surfaces (i.e., non-functionalized nanoparticles). This observation is consistent with 
previously published data that shows that hydrophilic chemistries are more readily 
internalized by AM and DCs [47, 60]. As expected, the absence of the MMR did not 
negatively affect the enhanced uptake of galactose-functionalized nanoparticles. The 
enhanced AM activation profile observed following co-culture with di-mannose 
functionalized nanoparticles was also found to be dependent upon the presence of the 
MMR (Figures 5.5 and 5.6). This suggests that not only does the MMR promote 
internalization of the di-mannose functionalized, but also that engagement of the MMR 
further enhances the expression of cell surface markers and cytokine production. Taken 
together, these results imply a specific engagement of the receptor in the recognition of 
di-mannose functionalized nanoparticles and in the downstream cascade of events that 
promotes the cytokine production. This indicates that the di-mannose functionalized 
nanoparticles have “pathogen-like” capabilities with respect to their internalization and 
APC activation capabilities. 
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Together, these studies indicate that targeting CLRs is an effective strategy in 
the design of efficacious intranasal vaccines. In addition, enhanced expression of 
activation markers initiating an immune response and a positive feedback loop with 
enhanced cytokine production can be achieved differently depending on the specific 
receptor engaged in recognizing the functionalized groups. The functionalized 
nanoparticles provide a versatile and robust platform that can be used to tailor the 
immune response. Finally, the ligands can be combined, via the use of cocktails of 
differently functionalized polyanhydride nanoparticles, which may trigger a specific set 
of PRRs and generate a potent immune response, much like that induced by 
pathogens. This mode of activating the immune system represents a viable strategy in 
the rational design of efficacious intranasal vaccines. 
5.6 Conclusions  
The approach outlined in this present work demonstrates that rational design of 
efficacious vaccine adjuvants can be achieved by targeting CLRs on APCs. Specifically, 
we describe the functionalization of polyanhydride nanoparticles with two conserved 
carbohydrate structures commonly found on the surface of respiratory pathogens, di-
mannose and galactose. The addition of these carbohydrates significantly enhanced the 
intrinsic adjuvant activity of our polyanhydride nanovaccine platform by further 
upregulating AM surface expression of MHC I and II, CLRs, and T cell co-stimulatory 
molecules as well as secretion of pro-inflammatory cytokines. Moreover, we 
demonstrate that di-mannose functionalized polyanhydride nanoparticles specifically 
engaged the macrophage mannose receptor in order to enhance nanoparticle uptake 
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and activate AM. These studies provide important insights into the design and rational 
selection of potential intranasal vaccine candidates that can be modified to improve their 
adjuvanticity. 
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Supplemental Figure 5.1 Di-mannose functionalized nanoparticles enhanced 
internalization by engaging the macrophage mannose receptor on bone marrow-derived 
macrophages (BMM). Percent of wild type () and MMR-deficient (MMR-/-; ) BMM that 
internalized nanoparticles after 48 hrs. Data are expressed as the mean ± the SEM of three 
independent experiments performed in triplicate. * represents a statistically significant difference 
between wild type and MMR-/- BMM within a treatment at p < 0.05. # represents a statistically 
significant difference from the non-functionalized nanoparticle treatment group for wild type 
BMM. 
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Supplemental Figure 5.2 Di-mannose functionalized nanoparticles enhanced bone 
marrow-derived macrophage (BMM) expression of MHC, T cell co-stimulatory 
molecules and CLRs by engaging the macrophage mannose receptor. After stimulation 
with non-functionalized (NF) or functionalized nanoparticles for 48 hrs, wild type () and MMR-
deficient (MMR-/-; ) BMM were harvested and analyzed by flow cytometry for surface 
expression of (A) MHC I, (B) MHC II, (C) CD86, (D) CD40, (E) MGL, or (F) CIRE. Data are 
expressed as the mean ± the SEM of three independent experiments performed in triplicate. * 
represents a statistically significant difference between wild type and MMR-/- BMM within a 
treatment at p < 0.05. MFI = mean fluorescence intensity. 
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Supplemental Figure 5.3  Di-mannose functionalized nanoparticles enhanced bone 
marrow-derived macrophage (BMM) pro-inflammatory cytokine production by engaging 
the macrophage mannose receptor. After stimulation with non-functionalized (NF) or 
functionalized nanoparticles for 48 hrs, culture supernatants from wild type () and MMR-
deficient (MMR-/-; ) BMM were harvested and assayed for (A) IL-1β, (B) TNF-α, (C) IL-6, and 
(D) IL-12p40. Non-stimulated cells (NS) were used as a negative control. Data are expressed as 
the mean ± the SEM of three independent experiments performed in triplicate. * represents a 
statistically significant difference between wild type and MMR-/- BMM within a treatment at p < 
0.05. 
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK  
6.1 Conclusions 
This work was focused on the design of surface functionalized polyanhydride 
nanoparticles as novel adjuvants by targeting C-type lectin receptors (CLRs) as a 
strategy to tailor the immune response for the rational design of targeted vaccines 
against particular pathogens. This study evaluated amphiphilic polyanhydride 
nanoparticles based on 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-
bis(p-carboxyphenoxy)hexane (CPH) as adjuvants and targeted delivery systems. The 
two saccharides used to modify the surface of these nanoparticles were galactose and 
di-mannose, which target the macrophage galactose lectin (MGL) and the macrophage 
mannose receptor (MMR) respectively.  
The high throughput synthesis and characterization of these functionalized 
nanoparticles was addressed in Chapter 4. A high throughput set up operated by 
LabView® was used for the synthesis of the nanoparticles and for their surface 
functionalization. Optimal conditions were determined in order to maintain nanoparticle 
morphology and a consistent and reproducible concentration of carbohydrate attached 
to the surface.  
The evaluation of the capabilities of these functionalized polyanhydride 
nanoparticles to target specific CLRs on alveolar macrophages (AM) was presented in 
Chapter 5. In this work, the study of internalization and activation (i.e., cell surface 
marker expression, cytokine production, and reactive nitrogen species production) of 
AM treated with functionalized polyanhydride nanoparticles was investigated. In 
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addition, mechanistic studies were performed in order to assess the engagement of 
CLRs in the recognition of these novel nanoparticles and the downstream events after 
crosslink of the CLRs with specific ligands. The results obtained provide valuable 
insights into the selection of appropriate functionalization motifs for the development of 
intranasal vaccine formulations, depending on the particular pathogen. The adjuvant 
capacity of polyanhydride nanoparticles and their potential to include ligands to target 
specific receptors provides a versatile platform for the rational design of vaccines. In 
addition to the multiple parameters that can be varied (i.e. polymer chemistry, particle 
size, antigen loading and delivery route) to optimize vaccine delivery and protective 
immunity, the functionalization of these particles with different ligands adds an 
advantage that helps tailor the immune response in an appropriate manner for the 
design of vaccine formulations against specific diseases. 
6.2 Future Work  
The results of this research project set the stage for the study of new applications 
and further investigations that can be performed with these functionalized polyanhydride 
nanoparticles.  
6.2.1 Library synthesis and vaccine formulation 
As suggested before, the ligand density may be an important factor to take into 
consideration when targeting C-type lectin receptors. The ligand density may change 
the immunological potency of the resultant response [1]. This suggests that varying the 
amount of carbohydrate attached to the nanoparticle should be investigated to 
determine the effect of the density of specific ligands (i.e., di-mannose or galactose).  
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The high throughput set up described in Chapter 4 provides the ability to 
synthesize a library of functionalized polyanhydride nanoparticles by varying the amount 
of saccharides attached. Specific technical aspects should be investigated such as the 
systematic variation of the saccharide concentration on the surface of nanoparticles. 
One approach is the variation of the ethylenediamine or linker (Figure 6.1) 
between the deprotected saccharide and the nanoparticles. In the protocol described in 
Chapter 4, 10 equivalents of ethylenediamine were employed, because an excess of 
equivalent was needed based on the density of carboxylic acids calculated to be 
present on the surface of 50:50 CPTEG:CPH polyanhydride nanoparticles [2]. By 
varying the number of equivalents of ethylenediamine (attached in the first reaction 
described in Chapter 4), the molecules available for the second reaction will change as 
well. An alternative approach is to change the number of equivalents of deprotected 
saccharides. This option may lead to a higher number of free ethylenediamine groups 
on the surface of the nanoparticles. In addition, a combination approach of varying both 
the number of ethylenediamine equivalents and saccharides can be evaluated.  
 Figure 6.1 Schematic representation of saccharides attached.  
mannose, (B) lactose, and (C) galactose attached to polyanhydride nanoparticles  is 
represented.(  ) Highlights
ethylenediamine linker used for the amine carboxylic acid coupling reaction. 
 
Another approach is to evaluate a different method to attach the saccharide to 
the nanoparticle, such as a biospecific 
tetrameric 52,800 Da MW protein, could be attached to the surface of polyanhydrides by 
an amine coupling reaction 
saccharides may be studied. This may facilitate the rapid variation of saccharides on the 
surface of nanoparticles.  
After designing a systematic method to change the ligand density on the surface 
of the nanoparticles, further studies could be performed to evaluate how the ligand 
density affects the activation of antigen presenting cells (APCs). In addition
chemistries of polyanhydride nanoparticles can be functionalized in order to evaluate 
how the chemistry and functionalization together affect the activation of APCs. 
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biotin-streptavidin linkage. Streptavidin, a 
[3]. Then, different methods of producing biotinylated 
-
 highlight the 
, different 
 
 The set up described in Chapter 4 enhances the throughput of the nanoparticle
synthesis and functionalization process. Therefore, a 3D library can be created by 
varying not only the amount of saccharides attached to the surface of the nanoparticles, 
but also the saccharides themselves along with the polymer chemistry (
 
Figure 6.2 Schematic representation of the proposed 3D library.  
how a 3D library can be synthesized by simultaneously varying the saccharide, the saccharide 
concentration, and polymer chemistry. 
 
Further studies can evaluate 
interaction with APCs treated with functionalized polyanhydride nanoparticles, in order 
to study how the immune response is tailored by the targeting of different CLRs. 
Biodistribution studies after intrana
may provide valuable information, identifying how immune cells internalize these 
particles and transport them to the draining lymph nodes.  
The efficacy of these functionalized polyanhydride nanoparticles
vivo as a vaccine formulation encapsulating an antigen against a specific disease. This 
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process may be challenging if the encapsulation of the antigen is performed prior to the 
surface functionalization by using a method such as anti-solvent nanoprecipitation. 
During the functionalization reactions, the nanoparticles are in aqueous environment, 
which causes some degradation, leading to the premature release of the antigen. Since 
these antigens may have amine motifs, these groups might compete with the amine 
carboxylic coupling reaction, potentially decreasing the amount of saccharides attached 
to the surface of the nanoparticles. In addition, the loading of antigen may be affected 
by the functionalization process.  
6.2.2 Novel ligands targeting other CLRs 
The array of CLRs that may be targeted is wide and functionalization with 
different ligands is another direction that might be explored. Several ligands are 
recognized by a single CLR and the crosslinking with different ligands may lead to a 
different response of the cell [4, 5]. Several ligands should be engineered to target 
diverse CLRs (Table 6.1). It is important to emphasize that different ligands might be 
recognized by several CLRs, providing synergy among different CLRs causing a potent 
immune response. For example, mannose is recognized by MMR and CIRE receptor 
and N-acetylglucosamine is recognized by MMR and the Endo-180 receptor, and a 
combination of mannose- and N-acetylglucosamine may produce a different 
downstream response upon crosslinking with these receptors. The outcome after 
crosslinking between ligands and receptors could be varied. Some studies suggest that 
the Endo-180 receptor enhances the internalization of glycosylated ligands to 
endosomal compartments, and the downstream outcome of this observation has not 
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been determined [6]. The biological effect of crosslinking β-glucan and Dectin-1 
receptors has been studied and it has been shown that both cell surface marker 
expression and production of cytokines such as IL-4 and IL-12 are enhanced [7-9]. 
 
Table 6.1 Rational selection of ligands to target specific CLRs 
Ligand CLRs  that might be targeted 
Fucose  MMR, Endo-180 receptor 
N-acetylglucosamine MMR, Endo-180 receptor, Langerin 
High mannose structures MMR, CIRE receptor 
β-glucan Dectin-1 
N-acetylgalactosamine MGL2 
Mannose 6 phosphate  M6P Mannose 6 phosphate receptor 
 
6.2.3 Novel applications: from gene delivery to cancer vaccines 
The diverse outcomes obtained with different functionalized nanoparticles may 
provide a versatile platform that could be used for several applications beyond vaccine 
design. It is known that several strategies (liposomes, mannose-DNA complexes, etc.) 
targeting the mannose receptor have enhanced the delivery of genes into macrophages 
[10-13]. These insights may be useful to design a DNA vaccine adjuvant by combining 
the adjuvant properties of polyanhydride nanoparticles with targeting using MMR to 
improve transfection efficiency.  It is well known that MMR leads to the internalization of 
a glycosylated antigen into the endosomal compartment. As a consequence, a limitation 
of transfecting genes with this approach may be DNA degradation in endosomal 
compartments and its escape from this compartment. New strategies that could be used 
to promote the escape of DNA or RNA molecules from the endosome include the 
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addition of endosomolytic components such as adenovirus particles and influenza 
peptides [10].  
We have performed some preliminary work in this area by encapsulating an RNA 
molecule (i.e., 3UP8C3PEG molecule provided by Joonbae Seo from Dr. Ravi Singh’s 
laboratory at ISU) and studying its release from 50:50 CPTEG:CPH nanoparticles 
(Figure 6.3). Further in vivo and in vitro studies may be performed with functionalized 
nanoparticles in order to assess the capacity of these nanoparticles to transfect DNA or 
RNA molecules.  
 
 
 
 
Figure 6.3 RNA release from 50:50 CPTEG:CPH nanoparticles. The release study was 
performed at constant agitation at 37°C in an aqueou s buffer for 30 days.  
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Another application that can be studied is the development of cancer vaccines 
using functionalized polyanhydride nanoparticles. It is known that the targeting of the 
mannose 6 phosphate (M6P) receptor (a receptor localized as a transmembranal 
protein in the Golgi) provides tumor suppressor properties [14]. A similar capability has 
been attributed to the targeting of MGL. Transformation or glycan modifications at the 
cell surface may provide oncogenic signaling (tumor transformation, invasion and 
metastasis) [15]. MUC1 glycoprotein is an example of a protein present on the surface 
of mammary cells, whose expression is increased on breast cancer cells. This is a 
tumor-associated glycoform that can be recognized by MGL by promoting its 
internalization and presentation on MHC I and II complexes. This specific recognition 
and presentation has positive implications for the design of cancer vaccines [16, 17]. 
The tumoricidal cellular recognition in addition to enhancement of the uptake of 
glycosylated antigens are important attributes that make galactose-functionalized 
nanoparticles promising candidates for the development of cancer vaccines.  
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 APPENDIX: TAILORING THE IMMUNE RESPONSE OF BONE 
MARROW DERIVED MACROPHAGES 
Section to be 
A1.1 Internalization assessment
The internalization of quantum dot loaded functionalized nanoparticles was 
evaluated using confocal microscopy.  Cell membrane was stained using Oregon 
Green® 488 conjugated WGA (Invitrogen) and images corroborate the a
internalization of nanoparticles as supposed to particles associated to cell membrane
(Figure A1.1). These results validate the technique to quantify internalization of 
nanoparticles using flow cytometry. 
Figure A1.1 Confocal Microscopy qualitativ
determine the role of internalization of nanoparticles, QDs loaded nanoparticles were used to 
stimulate BMM (A) and AM (B) 
did not internalize nanoparticles and white arrows highlight internalized nanoparticles. Prior 
staining for flow cytometry analysis, some samples were separated and stained for confocal 
microscopy analysis verifying that QDs loaded nanoparticles were actually internalized by 
macrophages. Cells were fixed on glass coverslips and stained with Oregon Green® 488 
conjugated WGA (Invitrogen) following the procedure recommended by the provider. Coverslips 
were mounted using ProLong Gold with DAPI mounting medium (Invitrogen). 
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submitted to Biomaterials as supplementary 
 
 
e assessment of internalization. 
harvest on wild type B6 mice. Yellow arrow show cells that 
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In order to 
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A1.2 Cell surface marker expression and cytokine production 
Similarly to the results presented in Chapter 5, the activation of bone-marrow 
derived macrophages (BMMs) was evaluated measuring cell surface marker 
expression and cytokine production. The results herein presented are similar to the 
ones obtained on Chapter 5 were AM were the main subject of investigation.  
The expression of MHC I and MHC II is fundamental for antigen presentation.  
The stimulation of BMMs with galactose and di-mannose functionalized nanoparticles 
resulted in an up-regulation in the expression of these two markers. The expression of 
co-stimulatory molecules, i.e. CD40 and CD86, needed for the activation of T cells, was 
enhanced as well by galactose and di-mannose functionalized polyanydride 
nanoparticles in comparison to the non-functionalized group (Figure A1.2). 
Internalization resulted required for the expression of CD40, will no difference was 
observed in the percentage of cells positive for MHC I, MHC ii and CD86 and positive 
for nanoparticles, suggesting that only interaction of cells with particles, as well as the 
microenvironment generated by stimulation, was sufficient for the expression of these 
markers (Figure A1.2). The expression of CLRs was enhanced depending on the 
stimulation group. The expression of the macrophage mannose receptor (MMR) was 
enhanced by di-mannose functionalized nanoparticles; similarly this group was the main 
group that enhanced the expression of CIRE receptor. The macrophage galactose lectin 
(MGL) was enhanced mainly by galactose-functionalized nanoparticles (Figure A1.3). 
These results suggest that the target of these specific CLRs improved the expression of 
markers needed for antigen presentation and T-cell activation.  
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The internalization of specific functionalized nanoparticles enhanced the 
expression of specific CLRs, since there was a significant difference in the percentage 
of cells double positive for a specific CLR and nanoparticles depending on the 
functionalization (Figure A1.3). The Internalization of di-mannose functionalized 
nanoparticles enhanced the expression of MMR and CIRE receptor, while the 
internalization of galactose functionalized nanoparticles up regulated the expression of 
MGL.  These results suggest that the internalization of nanoparticles was effectively 
mediated by specific receptors depending on the functional groups located on the 
surface of nanoparticles. 
The presence or absence of cytokines is fundamental to tailor the immune 
response. The production of pro-inflammatory cytokines, IL-12p40 and IL-10 was 
measured on the supernants of stimulated cells.   The production of pro-inflammatory 
cytokines (i.e. IL-6, IL-1β and TNF-α) was enhanced mainly by di-mannose 
functionalized nanoparticles compared with the non-functionalized group, but no 
significant amounts of reactive nitrogen species (RNS) were produced by BMM under 
any stimulation treatment (Figure A1.4). This results suggest that the simulation with di-
mannose functionalized nanoparticle are able to induce a secondary signal (pro-
inflammatory cytokines) for the activation of T cells.  The production of IL-12p40 (which 
main function is direct the immune response towards a Th1 pathway)  was enhanced as 
well by the di-mannose functionalization, and the galactose functionalization resulted in 
a down regulation on its production (Figure A1.4). There was no secretion of IL-10 
under any stimulation group (data not shown). These results suggest that even when 
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CIRE, MMR and MGL are CLRs that mediate the internalization of antigens, different 
immune outcome can be generated depending on the CLR that is targeted.  
 
   
 
Figure A1.2 Cell surface expression of activation markers. Bone-marrow derived 
macrophages (BMMs) harvested from wild type B6 mice were stimulated with non-
functionalized (NF) nanoparticles and different functionalized nanoparticle treatments. Non-
stimulated (NS) and LPS-stimulated groups were included as negative and positive controls, 
respectively. After 48 h, cells were stained and analyzed by flow cytometry for surface 
expression of (A) MHC I, (B) MHC II, (C) CD86, and (D) CD40. Di-mannose and galactose 
modified nanoparticles effectively enhanced the expression of MHCI, MHCII, CD86 and CD40 
compared with the NF nanoparticles. In order to determine the role of nanoparticle 
internalization, QD-loaded nanoparticles were used to stimulate BMM. Percentage of cells 
positive for (E) CD86 and (F) CD40 were identified in nanoparticle+ (double positive, ) and 
nanoparticle- (positive for marker/negative for nanoparticle, ) populations. The mean ± 
standard error of three independent experiments performed in triplicate is shown. MFI = mean 
fluorescent intensity. Different letters indicate statistical differences among treatment groups 
(Tukey HSD test, p < 0.05). (*) represents statistically significant differences between 
nanoparticle+ and nanoparticle- groups (T-test, p < 0.05). 
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Figure A1.3 Cell surface expression of CLRs. Bone-marrow derived macrophages (BMMs) 
harvested from wild type B6 mice were stimulated with non-functionalized (NF) nanoparticles 
and different functionalized nanoparticle treatments. Non-stimulated (NS) and LPS-stimulated 
groups were included as negative and positive controls, respectively. After 48 h, cells were 
stained, and analyzed by flow cytometry for surface expression of (A) MMR, (B) CIRE receptor, 
and (C) MGL. The data indicate that while di-mannose functionalization enhanced the 
expression of MMR and galactose functionalized nanoparticles enhanced the expression of 
MGL, the expression of CIRE receptor by the different functionalization groups was similar to 
that of the NF group. In order to determine the role of nanoparticle internalization, QD-loaded 
nanoparticles were used to stimulate BMM. Percentage of cells positive for (D) MMR, (E) 
CIRE, and (F) MGL were identified in nanoparticle+ (double positive, ) and nanoparticle- 
(positive for marker/negative for nanoparticle, ) populations. The mean ± standard error of 
three independent experiments performed in triplicate is shown. MFI = mean fluorescent 
intensity. Different letters indicate statistical differences among treatment groups (Tukey HSD 
test, p < 0.05). (*) represents statistically significant differences between nanoparticle+ and 
nanoparticle- groups (T-test, p < 0.05). 
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Figure A1.4 Cytokine production and reactive nitrogen species quantification.  Bone-
marrow derived macrophages (BMMs) harvested from wild type B6 mice were stimulated with 
non-functionalized (NF) nanoparticles and different functionalized nanoparticle treatments. Non-
stimulated (NS) and LPS-stimulated groups were included as negative and positive controls, 
respectively. After 48 h, supernatants were collected and used to measure the concentration of 
the pro-inflammatory cytokines (A) IL-6 (B) IL-1β, (C) TNF-α, as well as (D) IL-12p40 and IL-10. 
In these studies, IL-10 was not detected for any of the treatments (data not shown). BMM 
stimulated with LPS induced the following amounts of cytokines: 10,194.80 ± 148.9 pg/mL for 
IL-1β, 95,787.70 ± 175.05 pg/mL for IL-6,  7,853.5 ± 122.18 pg/ml for TNF-α,  and 4,465.33 
±134.69 for IL-12p40). (F) Nitrate concentration was measured on supernants by a Griess 
assay as an indirect method of quantification of reactive nitrogen species. The mean ± standard 
error of three independent experiments performed in triplicate is shown. Different letters entail 
statistical differences among treatment groups (Tukey HSD test, p < 0.05). 
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A1.3 Engagement of MMR 
The engagement of the MMR in the recognition of di-mannose functionalized 
nanoparticles was corroborated using BMM derived from bone-marrow of macrophage 
mannose receptor knock out (MMR KO) mice. Statistical differences was observed not 
only in the rate of internalization of particles (Figure A1.5), but also in the expression of 
cell surface markers (i.e. activation markers and CLRs) (Figures A1.6 and A1.7), and 
the production of cytokines (Figure A1.8) only when MMR KO BMM were stimulated 
with the di-mannose functionalized polyanhydride nanoparticles.  
 
 
 
 
 
 
Figure A1.5 Internalization of functionalized and non-functionalized nanoparticles.  Bone-
marrow derived macrophages (BMMs) were stimulated with QD-loaded functionalized and 
non-functionalized (NF) nanoparticles. After 48h, cells harvested from wild type () or MMR KO 
mice () were stained and analyzed by flow cytometry. Percentage of BMM that internalized 
nanoparticles was measured as percentage of cells that were positive for QD-loaded 
functionalized and non-functionalized nanoparticles (with appropriate background subtraction). 
The mean ± standard error of three independent experiments performed in triplicate is shown. 
(*) represents statistically significant differences between BMM harvested from wild type or 
MMR KO mice (T-test, p < 0.05). 
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Figure A1.6 Effect of the knockout of MMR on cell surface marker expression of 
activation markers.  Bone-marrow derived macrophages (BMMs) were stimulated with QD-
loaded functionalized and non-functionalized (NF) nanoparticles. After 48h, cells harvested from 
wild type () or MMR KO mice () were stained and analyzed by flow cytometry for surface 
expression of (A) MHC I (B) MHC II, (C) CD86 and (D) CD40. The mean ± standard error of 
three independent experiments performed in triplicate is shown. MFI = mean fluorescent 
intensity. (*) represents statistically significant differences between BMM harvested from wild 
type or MMR KO mice (T-test, p < 0.05). 
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Figure A1.7 Effect of the knockout of MMR on the expression of CLRs.  Bone-marrow 
derived macrophages (BMMs) were stimulated with QD-loaded functionalized and non-
functionalized (NF) nanoparticles. After 48h, cells harvested from wild type () or MMR KO mice 
() were stained and analyzed by flow cytometry for surface expression of (A) CIRE receptor 
and (B) MGL. The mean ± standard error of three independent experiments performed in 
triplicate is shown. MFI = mean fluorescent intensity. (*) represents statistically significant 
differences between BMM harvested from wild type or MMR KO mice (T-test, p < 0.05). 
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Figure A1.8 Effect of the knockout of MMR on the production of cytokines. Bone-marrow 
derived macrophages (BMMs) were stimulated with QD-loaded functionalized and non-
functionalized (NF) nanoparticles. After 48h, supernants were collected to measure cytokine 
concentration on AM cultures harvested from wild type () or MMR KO mice (). The mean ± 
standard error of three independent experiments performed in triplicate is shown. (*) represents 
statistically significant differences between BMM harvested from wild type or MMR KO mice 
(T-test, p < 0.05). 
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